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HYDROGELS FOR DELIVERY OF Biodegradation is another possible environmental 
THERAPEUTIC COMPOUNDS response of hydrogels designed for drug delivery applica 
tions ( Knipe et al . , 2014 ; Hu et al . , 2012 ) . Polymers that 
CROSS - REFERENCE TO RELATED degrade by hydrolysis , such as polyanhydrides ( Torres et al . , 
APPLICATIONS 2007 ; Lopac et al . , 2009 ) , poly ( orthoesters ) ( Hoffman , 1991 ; 
Thombre et al . , 1985 ) , poly ( caprolactone ) , and poly ( lactic 
This application claims the benefit of U . S . Provisional acid ) and poly ( glycolic acid ) ( Lao et al . , 2008 ; Anderson et 
Pata n No . 62 / 103 . 446 , filed Jan . 14 . 2015 . the al . , 2012 ) have been used for drug delivery . 
entirety of which is incorporated herein by reference . Oral delivery of siRNA might be used for treating dis 10 eases of the gastrointestinal ( GI ) tract , such as inflammatory 
STATEMENT OF GOVERNMENT SUPPORT bowel diseases , and intestinal absorption could offer a route 
to systemic delivery . However , there are many extracellular 
The invention was made with government support under and intracellular barriers to oral siRNA delivery such as 
Grant No . CBET1033746 and DGE1110007 awarded by the proteolytic degradation ( Fattal et al . , 2008 ) , harsh pH envi 15 ronments ( Bouchie et al . , 2012 ) , and the necessity to achieve National Science Foundation . The government has certain intracellular delivery and endosomal escape while maintain rights in the invention . ing the integrity of the siRNA ( Whitehead et al . , 2009 ; 
Schiffelers et al . , 2003 ) , making successful oral delivery of INCORPORATION OF SEQUENCE LISTING siRNA a daunting task . The current strategies for oral 
20 delivery of siRNA to the intestine are relatively few in The sequence listing that is contained in the file named number , and they employ approaches that are only effective 
“ UTSBP1052US _ ST25 . txt " , which is 10 KB ( as measured in a limited capacity . Clearly there exists a need for 
in Microsoft Windows® ) and was created on Jan . 7 , 2016 , improved methods for oral delivery of therapeutic nucleo 
is filed herewith by electronic submission and is incorpo tides 
rated by reference herein . 25 Despite improvements in oral delivery of therapeutic 
proteins using hydrogel polymers , there nonetheless exists a 
BACKGROUND OF THE INVENTION significant need for improved control over release of the 
therapeutic in the small intestine from the hydrogel . Addi 
1 . Field of the Invention tionally , there remains a need for hydrogel polymers that are 
The present invention relates generally to the field of 30 Optimized for delivery of particular therapeutics . 
polymer chemistry and drug delivery . More particularly , it 
concerns hydrogel polymers that may be used for the oral SUMMARY OF THE INVENTION 
delivery of therapeutic compounds . 
2 . Description of Related Art In some aspects , the present invention overcomes limita 
Environmentally - responsive hydrogels , or hydrophilic , 35 tions in the prior art by providing pH - sensitive polymers that 
crosslinked polymer networks that undergo physicochemi - may be used for the improved oral delivery of therapeutic 
cal changes in response to one or more environmental compounds such as , e . g . , therapeutic proteins or nucleotides . 
stimuli , offer the specificity of highly tunable materials In some embodiments , the polymer is crosslinked with a 
combined with excellent biocompatibility ( Peppas et al . , peptide that is cleavable by an enzyme present in the small 
2006 ; Hoffman , 1991 ; Qiu and Park , 2001 ; Caldorera - Moore 40 intestine of a mammal or human such as , e . g . , trypsin . In 
and Peppas , 2009 ) . As the next generation of biomaterials , some embodiments , it has been observed that crosslinking 
these " intelligent ” networks are able to respond to or mimic with an enzyme - cleavable peptide linker can result in sig 
biological environments and processes such as vasculariza - nificant improvements in the release of a therapeutic from 
tion ( Bae et al . , 2012 ; Phelps et al . , 2009 ) , tumor physiology the pH - sensitive polymer in the small intestine . In some 
( Lin et al . , 2013 ; Liechty et al . , 2012 ) , endosomal compart - 45 aspects , pH - sensitive polymers that may be used for the oral 
ments ( Wong et al . , 2014 ; Forbes and Peppas , 2014 ; Liang delivery of a nucleotide or modified nucleotide therapeutic 
et al . , 2014 ) , or the extracellular matrix ( Guvendiren et al . , such as , e . g . , a siRNA or a miRNA , are also provided . In 
2013 ; Kirschner et al . , 2013 ) . This capability could be some embodiments , the pH - sensitive polymer may contain 
instrumental in achieving various biomedical advances , the therapeutic nucleotide in a polycationic nanoparticle 
including tissue regeneration and controlled delivery of 50 such as , e . g . , poly ( 2 - ( diethylaminoethyl ) methacrylate ) 
biological therapeutics ( Knipe et al . , 2014a ; Holzapfel et al . , ( PDEAEMA ) . 
2013 ) . As shown in the below examples , poly ( methacrylic acid 
Some hydrogels with pH - responsive behavior may be co - N - vinylpyrrolidone ) ( P ( MAA - CO - NVP ) ) polymer chains 
used as hydrogel systems for drug delivery applications were used to impart hydrophilic and pH - responsive behavior 
( Peppas et al . , 2000 ) . Polyanionic hydrogels such as poly 55 that controlled diffusion of enzymes into the polymer net 
( methacrylic acid ) ( PMAA ) exhibit complexation via hydro work due to pH - responsive complexation . The polymer 
gen bonding at low pH conditions , such as that of gastric chains were crosslinked by a facile bioconjugation reaction 
fluid , and undergo increased swelling due to ionization of with an oligopeptide rich in arginine and lysine groups 
the carboxylic groups at neutral pH conditions , such as that targeted for degradation specifically by the enzyme trypsin . 
of the intestine ( Kost et al . , 2012 ) . Thus , PMAA copolymers 60 Data regarding the synthesis , degradation , cytocompatibil 
have been utilized as oral drug delivery carriers or coatings ity , and therapeutic loading and release using the pH 
for their ability to protect a loaded therapeutic from dena responsive P ( MAA - CO - NVP ) crosslinked by the biodegrad 
turation and enzymatic degradation as it travels through able peptide are provided . 
gastric conditions yet swell and release the therapeutic at the An aspect of the present invention relates to a hydrogel 
site of absorption in the small intestine ( Torres - Lugo et al . , 65 polymer , wherein the polymer comprises a P ( MAA - CO 
2002 ; Torres Lugo et al . , 1999 ; Knipe et al . , 2014 ; Lowman NVP ) copolymer that is crosslinked with an enzymatically 
et al . , 1999 ; Carr et al . , 2009 ; Carr and Peppas . , 2010 ) . cleavable peptide linker , wherein the peptide linker is 3 - 25 
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amino acid residues in length and contains at least one lysine a therapeutic nucleic acid or polynucleotide . The nucleic 
amino acid . The peptide linker may be cleavable by a serine acid may be a small interfering RNA ( siRNA ) , a micro RNA 
protease ( e . g . , a trypsin , chymotrypsin , or elastase ) , car ( miRNA ) , a short hairpin RNA ( shRNA ) , or an antisense 
boxypeptidase , or aminopeptidase . In some embodiments , oligonucleotide . In some embodiments , the nucleic acid 
the peptide linker is cleavable by trypsin , wherein the trypsin 5 comprises at least one modified nucleic acid . In some 
is trypsin 1 , trypsin 2 , or mesotrypsin . In some embodi embodiments , the modified nucleic acid is a locked nucleic 
ments , the peptide is 4 - 20 , 5 - 15 , or 5 - 10 amino acid residues acid ( LNA ) . Alternately , the nucleic acid may consist of in length . The peptide may comprise or consists of non - modified or naturally occurring nucleotides . In some GRRRGK ( SEQ ID NO : 1 ) . The peptide may comprises the embodiments , the modified nucleic acid is a locked nucleic structure : acid ( LNA ) . In some embodiments , the therapeutic nucleic 
acid is comprised within or associated with the polycationic 
nanoparticle , wherein at least part of the polymer forms a 
HNNH , HNNH , coating around at least part of the polycationic nanoparticle . The polymer may be comprised in a pharmaceutical com 
position . In some embodiments , the pharmaceutical compo 
sition is formulated for oral delivery ( e . g . , as a tablet , 
capsule , or liquid preparation ) . In some embodiments , the 
I OH nucleic acid ( e . g . , siRNA , miRNA , shRNA ) is loaded or embedded in the polymer by a method comprising incubat 20 ing the nucleic acid in a loading solution ( e . g . , containing 
about 0 . 25 uM to about 4 uM of the nucleic acid in 
nuclease - free or essentially nuclease - free PBS at about pH 
5 . 5 ) , and the incubating may be for a period of time 
sufficient to allow the nucleic acid to enter the polymer . In HNNH some embodiments , the nucleic acid is loaded into the 
copolymer before or during crosslinking with the peptide 
In some embodiments , the polymer comprises the structure : linker . As shown in the below examples , loading the nucleic 
HN . HN . 
IZ 
N N m 
HN 
2 
- CH3 HN NH2 HN NH , 
HN 
HN HN 
trészlimeler ?? NH NH OH NH NH NH H3C m 
HN 
HNNH 
In some embodiments , the polymer has been crosslinked acid into the copolymer prior to crosslinking resulted in 
with the peptide through the use of a coupling reagent . The improved synthesis of the hydrogels and improved loading 
coupling reagent may be a carbodiimide . In some embodi - of the nucleic acid in the polymer , and these methods were 
ments , the polymer has been crosslinked with the peptide via 65 also observed to achieve gene knockdown in cells in experi 
an EDC - NHS reaction . ments where the nucleic acid was a siRNA . The polymer may comprise a polycationic nanoparticle . 
The polycationic nanoparticle may be substantially encap Another aspect of the present invention relates to a 
sulated within the polymer . In some embodiments , the method for loading a nucleic acid into a crosslinked hydro 
polycationic nanoparticle comprises or consists of poly ( 2 gel polymer , comprising : ( i ) incubating a copolymer com 
methoxy ethyl acrylate ) ( PMEA ) , poly ( 2 - ( diethylamino - 60 prising an acrylic acid , an acrylate monomer , or methacrylic 
ethyl ) methacrylate ) ( PDEAEMA ) , chitosan , poly ( ethyl acid in a loading solution comprising the nucleic acid ; and 
eneimine ) ( PEI ) , poly ( amidoamine ) ( PAMAM ) , poly subsequently ( ii ) crosslinking the copolymer with a cross 
( dimethylaminopropyl methacrylate ) ( PDMAPMA ) , poly linker . In some embodiments , the crosslinker is an enzy 
( 2 - aminoethyl methacrylate ) ( PAEMA ) , or poly ( 2 matically cleavable peptide crosslinker . In some embodi 
( dimethylaminoethyl ) methacrylate ) ( PDMAEMA ) . 65 ments , the copolymer comprises methacrylic acid and 
The polymer may comprise a therapeutic protein such as , N - vinylpyrrolidone . The nucleic acid may be a siRNA , an 
e . g . , insulin . In some embodiments , the polymer comprises miRNA , or an shRNA . In some embodiments , the copoly 
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mer is a P ( MAA - CO - NVP ) copolymer ; and wherein the ing incubation , microgels were lyophilized and dusted onto 
linker is an enzymatically cleavable peptide linker , wherein a carbon - tape coated aluminum stub , then coated with 5 nm 
the peptide linker is 3 - 25 amino acid residues in length and Pt / Pd . 
contains at least one lysine amino acid . The crosslinked FIG . 5 : Relative turbidity over time of 2 mg / ml solutions 
hydrogel polymer may be a hydrogel polymer of the present 5 of P ( MAA - CO - NVP ) microgels with degradable crosslinks 
invention or as described above . incubated in trypsin solutions ranging from 0 - 0 . 6 mg / ml 
Another aspect of the present invention relates to a trypsin in PBS ( 37° C . , pH 7 . 4 , N = 3 ) . 
method of treating a disease comprising administering a FIG . 6 : Relative turbidity over time of 2 mg / ml solutions 
pharmacologically relevant amount of a polymer of the of P ( MAA - CO - NVP ) microgels with degradable crosslinks 
present invention to a mammalian subject in need of such 10 inci incubated in PBS , 0 . 3 mg / ml trypsin in PBS , 0 . 6 mg / ml treatment . In some embodiments , said administration is oral . trypsin in PBS , rat gastric fluid * , or rat intestinal fluid ( 37° The subject may be a human . In some embodiments , the C . , pH 7 . 4 , N = 3 ) . * Gastric fluid error bars intentionally not disease is inflammatory bowel disease , Crohn ' s disease , shown to simplify the plot ; error is + 0 . 24 on average in a diabetes , a complication from diabetes , or celiac disease . 
As used herein the specification , “ a ” or “ an ” may mean 15 5 consistent manner across the period of the study . FIG . 7 : Activity assay of 0 . 6 mg / ml trypsin incubated with one or more . As used herein in the claim ( s ) , when used in 
conjunction with the word " comprising ” , the words “ a ” or various concentrations of P ( MAA - CO - NVP ) microgels con 
" an " may mean one or more than one . taining degradable crosslinks for 90 minutes , and then 
The use of the term “ or ” in the claims is used to mean deactivated with 0 , 80 , or 160 ul DMEM ( 37° C . , PH 7 . 4 , 
“ and / or ” unless explicitly indicated to refer to alternatives 20 N = 3 ) . Trypsin activity in the samples receiving no DMEM 
only or the alternatives are mutually exclusive , although the is evidenced by the strong linear correlation . Both volumes 
disclosure supports a definition that refers to only alterna - of DMEM were sufficient quench trypsin activity . 
tives and “ and / or . ” As used herein “ another ” may mean at FIGS . 8A - 8C : Activity assay of various trypsin concen 
least a second or more . trations incubated ( FIG . 8A ) without microgels ( FIG . 8B ) 
Throughout this application , the term “ about ” is used to 25 with 2 mg / ml P ( MAA - co - NVP ) microgels containing 
indicate that a value includes the inherent variation of error degradable crosslinks for 90 minutes , and ( FIG . 8C ) deac 
for the device , the method being employed to determine the tivated at 70° C . for 5 minutes ( degradation at 37° C . , pH 
value , or the variation that exists among the study subjects . 7 . 4 , N = 3 ) . PBS ( O ) , 0 . 0375 mg / ml trypsin ( I ) , 0 . 075 mg / ml 
Other objects , features and advantages of the present trypsin ( O ) , 0 . 15 mg / ml trypsin ( O ) , 0 . 3 mg / ml trypsin ( O ) , 
invention will become apparent from the following detailed 30 and 0 . 6 mg / ml trypsin ( O ) . 
description . It should be understood , however , that the FIGS . 9A - 9B : Activity assay of 0 . 6 mg / ml trypsin incu 
detailed description and the specific examples , while indi - bated with various concentrations of P ( MAA - CO - NVP ) 
cating preferred embodiments of the invention , are given by microgels containing degradable crosslinks for 90 minutes , 
way of illustration only , since various changes and modifi - and then deactivated with 5 minutes incubation at ( FIG . 9A ) 
cations within the spirit and scope of the invention will 35 60° C . and ( FIG . 9B ) 70° C . or 80° C . ( degradation at 37° 
become apparent to those skilled in the art from this detailed C . , PH 7 . 4 , N = 3 ) . Incubation at either 70° C . or 80° C . was 
description . sufficient to deactivate trypsin . 
FIGS . 10A - 10B : Evaluation of degraded microgel effect 
BRIEF DESCRIPTION OF THE DRAWINGS on cell metabolism using an MTS cell proliferation assay 
40 ( Promega ) . Microgels were incubated in PBS or 1 . 2 mg / ml 
The following drawings form part of the present specifi - trypsin in PBS for 90 minutes at 37° C . , and then the enzyme 
cation and are included to further demonstrate certain activity was quenched by addition of media with serum . 
aspects of the present invention . The invention may be better ( FIG . 10A ) Murine fibroblast L929 and ( FIG . 10B ) murine 
understood by reference to one or more of these drawings in macrophage RAW 264 . 7 cells were incubated with degraded 
combination with the detailed description of specific 45 microgel solutions ranging from 0 . 43 - 2 mg /mL in culture 
embodiments presented herein . media for 8 h . Following removal of the microgel solutions , 
FIGS . 1A - 1B : P ( MAA - CO - NVP ) microgels with peptide the MTS assay was allowed to incubate for 90 min . Cell 
crosslinks in the dry state , crushed and sieved to < 30 proliferation is relative to the positive control ( N = 3 ) . Nega 
Particles were dusted onto a carbon - tape coated aluminum tive control ( bleach ) ( D ) , positive control ( culture media ) 
stub then coated with 10 nm Pt / Pd . ( FIG . 1A ) scale bar = 10 50 ( O ) , microgels ( o ) , microgels with trypsin ( $ ) . 
um ; ( FIG . 1B ) scale bar = 5 um ( HV = 15 . 00 kV , WD = 9 . 6 FIG . 11 : Loading efficiencies of degradable P ( MAA - CO 
mm ) . NVP ) microgels with peptide crosslinker after incubation in 
FIG . 2 : FT - IR spectra of GRRRGK ( SEQ ID NO : 1 ) PBS ( I ) and after microgel collapse in acid ( X ) . Insulin 
peptide ( ) , uncrosslinked P ( MAA - CO - NVP ) ( - ) , ( MW 5 . 8 kDa ) was loaded into the microgels . Loading 
and peptide crosslinked P ( MAA - CO - NVP ) ( ) samples 55 efficiency was based on amount of protein into microgels 
were pressed in a KBr disk . relative to initial amount in solution . Weight loading effi 
FIG . 3 : FT - IR spectra of peptide crosslinked P ( MAA - CO - ciency is weight of loaded protein relative to total weight of 
NVP ) at neutral pH ( ) and peptide crosslinked P ( MAA - microgel and protein . Microgels were loaded over 4 hours at 
CO - NVP ) degradation products following incubation with 37° C . ( N = 3 ) . 
SGF ( * * • * • * • * ) SIF ( - ) , SIF without pancreatin ( * * ••••••• ) 60 FIGS . 12A - 12D : Image of P ( MAA - CO - NVP ) microgel 
or a trypsin solution ( - - ) ; samples were lyophilized and crosslinked by degradable peptide and encapsulating poly 
pressed in a KBr disk . cationic nanogels taken by confocal laser scanning micros 
FIGS . 4A - 4F : SEM micrographs of microgels after 90 copy . FIG . 12A , Nanogels labeled with NBD - C1 ( green ) ; 
minutes incubation in FIG . 4A ) SGF ( scale = 10 um ) ; FIG . FIG . 12B , P ( MAA - CO - NVP ) microgel matrix labeled with 
4B ) SIF ( scale = 10 um ) ; FIG . 4C ) PBS ( scale = 10 um ) ; FIG . 65 TAMRA - cadaverine ( red ) ; FIG . 12C , green and red overlay 
4D ) SGF ( scale = 5 um ) ; FIG . 4E ) SIF ( scale = 5 um ) ; FIG . 4F ) showed nanogel distribution in microgel ; FIG . 12D , bright 
PBS ( scale = 5 um ) ; ( EHT = 5 . 00 kV , WD = 15 . 6 mm ) . Follow field image of microgel . ( Scale bar = 30 um ) . 
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FIG . 13 : Orthogonal view of Z - stack image of P ( MAA - incubated in PBS or various trypsin concentrations for 4 
co - NVP ) microgel crosslinked by degradable peptide and hours at 37° C . , then the trypsin was deactivated by 2x 
encapsulating polycationic nanogels taken by confocal laser addition of DMEM . Human adenocarcinoma Caco - 2 cells 
scanning microscopy . Nanogels labeled with NBD - C1 were incubated with degraded microgel solutions at various 
( green ) in P ( MAA - CO - NVP ) microgel matrix labeled with 5 concentrations for 18 hours . Following microgel incubation , 
TAMRA - cadaverine ( red ) . ( Scale bar = 30 um ) the MTS and LDH assays were used to evaluate cytotoxicity . 
FIG . 14 : Relative turbidity over time of various concen ( N = 3 ) . trations of P ( MAA - CO - NVP ) microgels with degradable FIGS . 26A - 26C : Evaluation of degraded microgel and crosslinks encapsulating nanogels during incubation in 0 . 6 trypsin exposure effect on cell metabolism using a MTS cell and 1 . 2 mg / ml trypsin in PBS ( 37° C . , pH 7 . 4 , N = 3 ) . " 10 proliferation assay ( Promega ) . Microgels were incubated in FIGS . 15A - 15B : Relative turbidity over the first 20 min PBS or various trypsin concentrations for 90 minutes at 37° utes of incubation of trypsin with various concentrations of 
P ( MAA - CO - NVP ) microgels with degradable crosslinks C . , then the trypsin was deactivated by incubation at 70° C . 
encapsulating nanogels ; FIG . 15A , 1 . 2 mg / ml trypsin ; FIG . for 5 minutes . Murine macrophage RAW 264 . 7 cells were 
15B , 0 . 6 mg / ml trypsin in PBS ( 37° C . , PH 7 . 4 , N = 3 ) . Initial 15 incubated with degraded microgel solutions at FIG . 26A ) 1 
decrease in relative turbidity was fitted with a linear fit mg / ml in OptiMEM ; FIG . 26B ) 1 mg / ml in DMEM ; or FIG . 
( R2 > 0 . 98 ) . 26C ) 0 . 4 mg / ml in OptiMEM for 18 hours . Following 
FIG . 16 : The microgel : trypsin weight ratio versus initial microgel incubation , the MTS assay was allowed to incubate 
rate of turbidity decrease was correlated with a linear fit for 90 min . Absorbance at 490 nm is relative to the positive 
( R2 = 0 . 98 ) . The relationship may be used to approximate 20 control ( culture media only , patterned bar ) ( N = 3 ) . 
degradation time of a known microgel : trypsin weight ratio . FIGS . 27A - 27C : Evaluation of degraded microgel and 
FIGS . 17A - 17B : BAEE activity assay of FIG . 17A , 1 . 2 trypsin exposure effect on cell metabolism using a LDH 
mg / ml trypsin ; FIG . 17B , 0 . 6 mg / ml trypsin incubated with membrane integrity assay ( Promega ) . Microgels were incu 
various concentrations of P ( MAA - CO - NVP ) microgels con - bated in PBS or various trypsin concentrations for 90 
taining degradable crosslinks for 90 minutes , and then 25 minutes at 37° C . , then the trypsin was deactivated by 
deactivated by 5 minutes incubation at 70° C . or addition of incubation at 70° C . for 5 minutes . Murine macrophage 
2x volume of DMEM ( degradation at 37° C . , pH 7 . 4 , N = 3 ) . RAW 264 . 7 cells were incubated with degraded microgel 
FIGS . 18A - 18C : Representative images obtained via solutions at FIG . 27A ) 1 mg / ml in OptiMEM ; FIG . 27B ) 1 
ImageStream analysis of microgels encapsulating fluores - mg / ml in DMEM ; or FIG . 27C ) 0 . 4 mg / ml in OptiMEM for 
cent nanogels incubated for 90 minutes in FIG . 18A ) 1 . 2 30 18 hours . Following microgel incubation , the LDH assay 
mg / ml trypsin ( scale bar = 7 um ) , FIG . 18B ) 0 . 6 mg / ml was used to evaluate cell viability ( N = 3 ) . 
trypsin ( scale bar = 7 um ) , or FIG . 18C ) pH 7 . 4 PBS ( scale FIG . 28 : Representative siRNA loading efficiencies of 
bar = 10 um ) . Left : bright field , middle : green channel ( nano - degradable P ( MAA - CO - NVP ) microgels with peptide cross 
gels ) , right : overlay . linker and encapsulated polycationic nanogels . Loading 
FIGS . 19A - 19C : Histogram plots of particle size ( um ) 35 efficiency was based on amount of siRNA in microgels 
obtained by ImageStream analysis of microgels encapsulat - relative to initial amount in solution . Weight loading effi 
ing fluorescent nanogels incubated for 90 minutes in FIG . ciency is moles of siRNA relative to the weight of microgels . 
19A ) 1 . 2 mg / ml trypsin , FIG . 19B ) 0 . 6 mg / ml trypsin , or Microgels were loaded over 4 hours at room temperature 
FIG . 19C ) pH 7 . 4 PBS . ( N = 3 ) . 
FIGS . 20A - 20C : Representative images obtained via 40 FIGS . 29A - 29B : PAGE evaluation of siRNA degradation 
ImageStream analysis of microgels encapsulating fluores - after siRNA - loaded microgels were incubated in 1 ) 0 . 3 
cent nanogels incubated for minutes in FIG . 20A ) SGF mg / ml trypsin ; 2 ) rat intestinal fluid ; 3 ) rat gastric fluid ; 4 ) 
( scale bar = 7 um ) , FIG . 20B ) SIF ( scale bar = 7 um ) , or FIG . PBS ; or 5 ) SGF ; siRNA - complex nanogels incubated with 
20C ) 0 . 6 mg / ml trypsin ( scale bar = 7 um ) . Left : bright field , 6 ) 0 . 3 mg / ml trypsin ; 7 ) rat intestinal fluid ; 8 ) rat gastric 
middle : green channel ( nanogels ) , right : overlay . 45 fluid ; 9 ) PBS ; or 10 ) SGF ; or siRNA incubated with 11 ) 0 . 3 
FIGS . 21A - 21C : Histogram plots of particle size ( um ) mg / ml trypsin ; 12 ) rat intestinal fluid ; 13 ) rat gastric fluid ; 
obtained by ImageStream analysis of microgels encapsulat 14 ) PBS ; or 15 ) SGF . Solutions were run FIG . 29A ) imme 
ing fluorescent nanogels incubated for m0 minutes in FIG . diately after incubation in the buffers or FIG . 29B ) after an 
21A ) SGF , FIG . 20B ) SIF , or FIG . 20C ) 0 . 6 mg /ml trypsin . additional 15 minute incubation with heparin solution . 
FIGS . 22A - 22C : Representative images obtained via 50 FIGS . 30A - 30B : ( FIG . 30A ) , PAGE evaluation of siRNA 
ImageStream analysis of microgels encapsulating fluores - degradation after 1 ) siRNA - loaded microgels ; 2 ) siRNA and 
cent nanogels incubated for 120 minutes in FIG . 22A ) SGF nanogels ; 3 ) microgels with nanogels and siRNA ; and 4 ) 
( scale bar = 7 um ) , FIG . 22B ) SIF ( scale bar = 7 um ) , or FIG . microgels with nanogels and siRNA were incubated with 0 . 6 
22C ) 0 . 6 mg / ml trypsin ( scale bar = 7 um ) . Left : bright field , mg / ml trypsin for 90 minutes ; after 5 ) siRNA - loaded micro 
middle : green channel ( nanogels ) , right : overlay . 55 gels ; 6 ) siRNA and nanogels ; 7 ) microgels with nanogels 
FIGS . 23A - 23C : Histogram plots of particle size ( um ) and siRNA ; and 8 ) microgels with nanogels and siRNA were 
obtained by ImageStream analysis of microgels encapsulat - incubated with 0 . 6 mg / ml trypsin for 90 minutes followed by 
ing fluorescent nanogels incubated for 120 minutes in FIG . 15 minutes incubation with heparin ; and 9 - 10 ) incubation of 
23A ) SGF , FIG . 23B ) SIF , or FIG . 23C ) 0 . 6 mg /ml trypsin . siRNA with different concentrations RNase . ( FIG . 30B ) , 
FIG . 24 : Median particle size ( um ) values obtained by 60 PAGE evaluation of siRNA degradation after 1 ) siRNA on 
ImageStream analysis of microgels encapsulating fluores - ice ; 2 ) siRNA at room temperature ; 3 ) siRNA in pH 5 . 5 PBS ; 
cent nanogels at various time points during the 120 minute 4 ) siRNA in pH 8 . 5 PBS ; 5 ) siRNAloaded with microgels ; 
degradation period . 6 ) siRNA in 1 . 2 mg / ml trypsin ; 7 ) siRNA in 0 . 6 mg / ml 
FIGS . 25A - 25B : Evaluation of degraded microgel and trypsin ; 8 ) siRNA and microgels in 1 . 2 mg /ml trypsin ; 9 ) 
trypsin exposure effect on cell metabolism using a FIG . 65 siRNA and microgels in 0 . 6 mg / ml trypsin . 
25A ) MTS cell proliferation assay ( Promega ) and FIG . 25B ) FIGS . 31A - 31B : Confocal laser scanning microscopy 
LDH membrane integrity assay ( Promega ) . Microgels were fluorescent and bright field images of RAW 264 . 7 cells 
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incubated with FIG . 31A ) nanogels and FIG . 31B ) degraded hydrogel polymer compositions may be used to for oral 
microgels containing nanogels ( Scale bar = 20 um ) . delivery of a drug , such as a therapeutic polynucleotide or 
FIGS . 32A - 32B : Confocal laser scanning microscopy protein . The therapeutic polynucleotide or protein may 
fluorescent Z - stack orthogonal images of RAW 264 . 7 cells require at least some protection from degradation in the 
incubated with nanogels ( FIG . 32A ) and degraded microgels 5 digestive system ; for example , the therapeutic polynucle 
containing nanogels ( FIG . 32B ) ( Scale bar = 10 um ) . otide or protein may need protection from the acid condi 
FIGS . 33A - 33C : Confocal laser scanning microscopy tions ( e . g . , pH ~ 2 ) found in the stomach . As shown in the fluorescent and bright field images of RAW 264 . 7 cells below examples , hydrogel polymers are provided that may 
incubated with FIG . 33A ) degraded microgels with fluores protect the drug ( e . g . , therapeutic polynucleotide or protein ) cently - tagged nanogels and fluorescently - tagged siRNA ; ? 10 while it is in transit through the acidic conditions in the FIG . 33B ) fluorescently - tagged nanogels with fluorescently 
tagged siRNA ; and FIG . 33C ) fluorescently - tagged stomach , and then the polymer can swell in the more basic 
degraded microgels containing fluorescently - tagged nano conditions of the small intestine and allow for release of the 
gels and fluorescently - tagged siRNA ( Scale bar = 10 um ) . drug or therapeutic protein in the small intestine . In some 
FIGS . 34A - 34B : Gene knockdown by degraded and unde embodiments , the drug is a siRNA . In other embodiments , graded microgels containing nanogels , nanogels , commer - 15 the drug is a therapeutic protein such as insulin . The 
cially available Lipofectamine 2000 , or naked siRNA . A11 - polymers provided herein may be included in or used as a 
Stars Death and Negative Control ( Qiagen ) were used , and variety of pharmaceutical compositions , such as composi 
MTS cell proliferation assay was used to quantify silencing tions for oral delivery , e . g . , particles , tablets , capsules , 
efficiency ( N = 4 , * p < 0 . 05 ) . caplets , gel - seals , lozenges , syrups , sprays , and other liquid 
FIGS . 35A - 35D . Characterization and siRNA loading of 20 dosage forms . 
P ( DEAEMA - co - tBMA ) nanogels . FIG . 35A , Hydrody - Generally , the hydrogels may comprise hydrophilic poly 
namic diameter of nanogels at pH 5 . 5 ( ~ 122 nm ) and pH 7 . 4 mers or copolymers in the form of networks that can swell 
( ~ 110 nm ) . The nanogels display pH - responsive behavior in due to a high affinity for water ; however , the hydrogel may 
which they swell under pH conditions seen in the endosome be substantially insoluble due to the incorporation of chemi 
( n = 3 , Student ' s t - test , * p < 0 . 001 ) . FIG . 35B , Zeta potential 25 cal or physical crosslinks or other tie - points that keep the 
measurements indicate a positive surface charge of ~ 19 mV , chains together and do not allow them to dissolve in water . which decreases slightly after loading with negatively In some embodiments , the crosslinker is an enzymatically charged RNA ( n = 3 , Student ' s t - test , * p < 0 . 01 ) . FIG . 35C , cleavable peptide linker . Polymers or copolymer hydrogels Encapsulation and FIG . 35D , weight efficiency of siRNA may be responsive to pH changes . For example , in a solution loading into nanogels . Concentration of nanogels in loading 
solution was 0 . 125 mg / ml . Encapsulation efficiency was 30 with a lower pH ( e . g . , pH ~ 1 - 2 ) , pH - sensitive hydrogel 
calculated by measuring the concentration of siRNA remain networks may be largely hydrated , similar to other hydro 
ing in solution after particle loading ( C ) and expressed as philic copolymers ; however , at higher pHs ( e . g . , at pH ~ 6 - 7 ) , 
( Co - C . ) / c . * 100 ( n = 3 ) . carboxylic acid groups present in the polymer or copolymer 
FIG . 36 : TNF - a knockdown induced by siRNA carried by may deprotonate , and thus the polymer may attract more 
Lipofectamine LTX , P ( DEAEMA - CO - TBMA ) nanogels , or 35 water into the polymer network . Thus , the increased absorp 
degraded microgels containing P ( DEAEMA - co - tBMA ) tion of water into the polymer or copolymer may result in 
nanogels . Secreted TNF - a was significantly decreased in swelling , thus increasing the distance between the copoly 
cells incubated with carriers loaded with TNF - a siRNA VS mer chains . This increase in size , or swelling , can allow 
the carrier loaded with a control siRNA ( n = 4 - 8 , * p < 0 . 05 , increased release of a drug or therapeutic nucleotide or 
Student ' s t - test ) and vs no treatment . ( n = 4 - 8 , # p < 0 . 05 , 40 protein from the hydrogel network . The hydrogels may thus 
ANOVA ) . Non - degraded microgels loaded with TNF - a be used to orally deliver a therapeutic nucleotide or protein 
siRNA nanogels did not elicit any knockdown . to a mammalian subject such as a human ( e . g . , such that the 
therapeutic nucleotide or therapeutic protein is substantially 
DESCRIPTION OF ILLUSTRATIVE protected from acidic conditions , denaturation , or degrada EMBODIMENTS 45 tion in the stomach , and then is released in the small 
intestine ) . In some aspects , the present invention provides a In some embodiments , the copolymer comprises a poly P ( MAA - CO - NVP ) copolymer that is crosslinked with an mer of only the monomers referred to in the copolymer enzymatically cleavable peptide linker . The enzymatically 
cleavable peptide linker may be cleaved by a protease in the name ; for example , the P ( MAA - CO - NVP ) copolymer may be small intestine such as trypsin or chymotrypsin . In some 50 composed of a polymer made from only methacrylic acid 
embodiments . little or no cleavage of the peptide linker ( MAA ) and N - vinylpyrrolidone ( NVP ) . Nonetheless , as 
occurs due to proteases present in the stomach ( e . g . , pepsin , would be recognized by one of skill in the art , other 
etc . ) , but the peptide linker remains intact during passage monomers such as , e . g . , an acrylic acid monomer may be 
through the stomach and is selectively enzymatically included in the copolymer , without substantially altering one 
cleaved after entry into the small intestine . In some aspects , 55 or more of the properties ( e . g . , loading and release of a 
the polymers may be used to deliver a therapeutic such as therapeutic polynucleotide or protein , etc . ) of the copolymer . 
protein or nucleotide to the small intestine , with significantly As used herein , the term “ copolymer ” refers to a polymer 
reduced degradation from the stomach . In some embodi that comprises at least about 75 % , more preferably at least 
ments and as shown in the below examples , the polymers about 80 % , more preferably at least about 85 % , more 
provided herein can result in improved release of the thera - 60 preferably at least about 90 % , or at least about 91 , 92 , 93 , 94 , 
peutic ( e . g . , the therapeutic protein or nucleotide ) in the 95 , 96 , 97 , 98 , 99 , or 99 . 5 % of the monomers stated in the 
small intestine . name of the copolymer ( e . g . , methacrylic acid and N - vi 
nylpyrrolidone monomers in P ( MAA - CO - NVP ) . Additional 
I . HYDROGEL COPOLYMERS monomers that may be included in a copolymer include : 
65 ( i ) acrylic acid or acrylate monomers such as , e . g . , acrylic 
In some aspects of the present invention , improved hydro acid , itaconic acid ( IA ) , ethacrylic acid , propacrylic 
gel polymers are provided . In some embodiments , the acid , crotonic acid ( ( E ) - but - 2 - enoic acid ) , methacrylate 
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( 2 - methylprop - 2 - enoate ) , methyl methacrylate , ( Z ) - 3 - microparticles ( e . g . , with a mortar and pestle ) , and sieved to 
cyclohexylbut - 2 - enoic acid , butylmethacrylate ( butyl a desired size ( e . g . , less than 2000 um in size ) . Depending 
2 - methylprop - 2 - enoate ) , on the particular formulation , it may be desired to sieve the 
( ii ) N - vinylpyrrolidone ( 1 - Ethenyl - 2 - pyrrolidone or microparticles of dried hydrogel copolymer into a range of 
1 - ethenylpyrrolidin - 2 - one , NVP ) , isobetadyne ( 1 - ethe - 5 desired sizes , e . g . , about 10 - 2000 um , 25 - 1000 um , 10 - 500 
nylpyrrolidin - 2 - one ; molecular iodine ) ; N - vinyl suc um , 10 - 100 um , 10 , 20 , 30 , 35 , 40 , 45 , 50 , 55 , 60 , 65 , 70 , 75 , 
cinimide ( 1 - ethenylpyrrolidine - 2 , 5 - dione ) , 1 - ethe 80 , 85 , 90 , 100 , 200 , 300 , 400 , 500 , 1000 , 1500 , 2000 um or 
nylpyrrolidin - 2 - one , ain - 2 - one , trimethyl - [ 3 - ( 2 - methylprop - 2 - ( 3 - ( 2 - - 2 - any range derivable therein . 
enoylamino ) propyljazanium ; chloride ) , P ( VA - CO - In some embodiments , the hydrogel copolymers may be 
NVP ) ( ethenol ; 1 - ethenylpyrrolidin - 2 - one ) , and / or 10 used as or included in a pharmaceutical composition . It is 
( iii ) poly ( ethylene glycol ) ( P ( EG ) or PEG ) , poly ( ethylene envisioned that the pharmaceutical composition may include 
glycol ) methyl ether monomethacrylate ( PEGMMA ) , one or more additional agent such as a starch , cellulose , or 
and / or poly ( ethylene glycol ) methacrylate ( PEGMA ) . flavoring , etc . As such , these compositions may be formu 
In some aspects of the present disclosure , the hydrogel lated with an inert diluent or with an assimilable edible 
polymers or copolymers are partially crosslinked . In some 15 carrier , or they may be enclosed in hard - or soft - shell gelatin 
embodiments , the polymer or copolymer hydrogels may be capsule , or they may be compressed into tablets , or they may 
from about 5 - 75 % weight percent crosslinker . In some be incorporated directly with the food of the diet . In certain 
embodiments , the polymer or hydrogel may be from about embodiments , the hydrogel copolymer may be incorporated 
10 - 75 % , 20 - 65 % , 30 - 55 % , 40 - 50 % , 25 % , 30 % , 35 % , 40 % , with excipients and used in the form of ingestible tablets , 
45 % , 50 % , 55 % , 60 % , 65 % , or any range derivable therein , 20 buccal tables , troches , capsules , elixirs , suspensions , syrups , 
weight percent crosslinker . In some embodiments , copoly - wafers , and the like ( Mathiowitz et al . , 1997 ; Hwang et al . , 
mers comprising a range of crosslinking ( e . g . , at least 10 % 1998 ; U . S . Pat . Nos . 5 , 641 , 515 ; 5 , 580 , 579 and 5 , 792 , 451 , 
weight percent , more preferably at least 25 % weight percent , each specifically incorporated herein by reference in its 
or about 30 - 50 % crosslinking , etc . ) may display advanta - entirety ) . The tablets , troches , pills , capsules and the like 
geous properties ( e . g . , improved adsorption and release of a 25 may also contain the following : a binder , such as , for 
therapeutic protein , nanoparticle , or nucleotide in solutions example , gum tragacanth , acacia , cornstarch , gelatin or 
of differing pH , etc . ) . A variety of crosslinkers are known combinations thereof ; an excipient , such as , for example , 
and may be used in hydrogel polymers or copolymers of the dicalcium phosphate , mannitol , lactose , starch , magnesium 
present invention . In one particular embodiment , the cross stearate , sodium saccharine , cellulose , magnesium carbon 
linker is an enzymatically cleavable peptide . 30 ate or combinations thereof ; a disintegrating agent , such as , 
The ratio of monomers present in a copolymer may vary . for example , corn starch , potato starch , alginic acid or 
For example , when two monomers comprise the majority of combinations thereof ; a lubricant , such as , for example , 
a copolymer ( e . g . , the methacrylic acid and N - vinylpyrroli - magnesium stearate ; a sweetening agent , such as , for 
done monomers present in a P ( MAA - CO - NVP ) copolymer , example , sucrose , lactose , saccharin or combinations 
etc . ) , the ratio of the monomers may vary , e . g . , from about 35 thereof ; a flavoring agent , such as , for example peppermint , 
5 : 1 - 1 : 5 , 3 : 1 - 1 : 3 , or about 3 : 1 , 2 : 1 , 1 : 1 , 1 : 2 , or about 1 : 3 ; or oil of wintergreen , cherry flavoring , orange flavoring , etc . 
any range derivable therein ( e . g . , for the ratio of MAA : NVP When the dosage unit form is a capsule , it may contain , in 
present in a P ( MAA - CO - NVP ) copolymer ) . As shown in the addition to materials of the above type , a liquid carrier . 
below examples , particularly beneficial properties were Various other materials may be present as coatings or to 
observed for P ( MAA - CO - NVP ) copolymers that comprised a 40 otherwise modify the physical form of the dosage unit . For 
ratio of from about 2 : 1 to about 1 : 2 of MAA : NVP present instance , tablets , pills , or capsules may be coated with 
in the copolymer displayed significantly improved proper - shellac , sugar , or both . When the dosage form is a capsule , 
ties ( e . g . , loading and release of a therapeutic protein ) . it may contain , in addition to materials of the above type , 
Polymerization reactions to polymerize monomers may carriers such as a liquid carrier . Gelatin capsules , tablets , or 
be performed using methods known to one of skill in the art 45 pills may be enterically coated . Enteric coatings can reduce 
such as , e . g . , using UV light to promote polymerization . In denaturation of the composition in the stomach or upper 
some embodiments , the following reaction may be used to bowel where the pH is acidic . See , e . g . , U . S . Pat . No . 
polymerize monomers . Polymerizations may be carried out 5 , 629 , 001 . Upon reaching the small intestines , the basic pH 
in a 1 : 1 mixture of water and ethanol . The weight ratio of therein can substantially or completely dissolve the coating 
total monomers to solvent is from about 1 : 1 to about 1 : 10 . 50 and permits the composition to be released . A syrup may 
In some embodiments , the weight ratio of total monomers to contain a hydrogel copolymer and a sweetening agent ( e . g . , 
solvent is about 1 : 3 . Within this cosolvent , monomers may sucrose ) , a preservative ( e . g . , methyl or propylparabens ) , a 
be added at various molar ratios along with 1 mol % initiator dye , and / or flavoring ( e . g . , cherry or orange flavor , etc . ) . 
with respect to monomer . In some embodiments , the initiator Typically , any material used in preparing a dosage unit form 
is a photoinitiator such as , e . g . , Irgacure 184® . The mono - 55 should be substantially pharmaceutically pure and substan 
mer solution may then be introduced into a nitrogen envi - tially non - toxic in the amounts employed . 
ronment and purged with nitrogen to remove oxygen , a free 
radical scavenger . In some embodiments , the mixture is II . ENZYMATICALLY CLEAVABLE LINKERS 
homogenized in a flask and then polymerized , e . g . , for 30 
minutes in 100 mW / cm2 UV light using a UV source . After 60 In some aspects , the polymer of the present disclosure 
the polymerization , the polymer is purified from the unre - includes an enzymatically cleavable peptide as a linker . In 
acted monomer . In some aspects , the purification includes some embodiments , the enzymatically cleavable peptide 
the addition of an acid to precipitate the polymer . The crosslinks the carboxylic acid groups of the polymer or 
polymer may be centrifuged and the resuspended in water . hydrogel . A number of different protease cleavable peptides 
In some embodiments , the polymer is washed three times 65 may be used as linkers for the polymer of the present 
and then lyophilized over the course of 24 hours . In some disclosure . In some embodiments , the peptide comprises a 
embodiments , the polymers are crosslinked and crushed into protease cleavable site which is cleaved in the small intes 
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tine . In some embodiments , the protease cleavable peptide is polymer through the N - terminus and the G - amine group of 
cleaved by a protease present in the small intestine . In one the terminal lysine leaving the C - terminus of the lysine as a 
preferred embodiment , the protease cleavable peptide linker free carboxylate . 
is not cleaved by any proteases present in the stomach but In order to cross - link the polymer or hydrogel with a 
only by a protease found in the small intestine . In some 5 protease cleavable peptide , the polymer is reacted with a 
embodiments , the enzymatically cleavable peptide is a coupling agent to generate an activated carboxylic acid 
trypsin or chymotrypsin cleavable peptide . In some embodi - group . In some embodiments , the coupling agent generates 
ments , the enzymatically cleavable peptide may be selec an activated carboxylic acid group which is more susceptible 
tively cleavable by serine proteases , including trypsin and to the nucleophilic addition of the peptide . A non - limiting 
elastase , carboxypeptidase , or aminopeptidase . In some se in some 10 example of coupling agents include carbodiimide based 
embodiments , the enzymatically cleavable peptide is a coupling reagents , such as EDC , DCC , and DIC ; uronium 
trypsin cleavable peptide . Without being bound by any based coupling agents , such as BOP , PyBOP , HBTU , HATU , TBTU ; and acid halide generating reagents , such as phos theory , the trypsin protease may recognize a positively phorus pentachloride , oxalyl chloride , thionyl chloride , or charged amino acid residue and cleave the peptide on the 15 phosgene . In some embodiments , the coupling agent is used carboxy side of that positively charged amino acid reside . in conjunction with hydroxylamide or a hydroxylamine . In 
The trypsin protease is known to cleave a peptide on the some embodiment , the polymer is crosslinked with a pro carboxy side of a lysine or an arginine residue . tease cleavable peptide using a carbodiimide coupling 
A wide variety of different protease cleavable peptides reagent and a hydroxylamide such as N - hydroxysuccinim 
that comprise from 3 amino acid residues to 25 amino acid 20 ide . In some embodiments , the polymer is crosslinked with 
residues may be used in the present disclosure . In some a protease cleavable peptide with EDC and N - hydroxysuc 
embodiments , the protease cleavable peptide comprises cinimde . 
from 5 amino acid residues to 15 amino acid residues . In In some aspects , the polymer is crosslinked in an 1 : 1 ( v / v ) 
some embodiments , the protease cleavable peptide com - ethanol : water mixture with the coupling agent and NHS . 
prises from 5 amino acid residues to 10 amino acid residues . 25 The polymer may be added to the coupling reagent and NHS 
In some embodiments , the protease cleavable peptide com in a ratio of about 1 : 1 : 1 to about 6 : 3 : 1 polymer to coupling 
prises amino acid residues selected from lysine , arginine , or reagent to NHS . In some embodiments , the ratio of coupling 
glycine . In some aspects of the present disclosure , the reagent and NHS to polymer is added at about 6 : 3 : 1 poly 
protease cleavable peptide comprises at least one arginine or mer : EDC : NHS . The reagents are mixed and / or vortexed and 
lysine and a C - terminus lysine to form a trypsin cleavage sin cleavage 30 then the pH of the solution is adjust to about 8 using a strong 
site . Some non - limiting examples of trypsin cleavable pep base such as a metal hydroxide . The peptide is added to the 
tide include , but are not limited to , GRK , GKK , GRGK solution in a ratio of 1 : 1 to about 5 : 1 polymer to peptide . The 
( SEO ID NO : 2 ) , GKGK ( SEQ ID NO : 3 ) , GRRGK ( SEQ mixture is reacted for about 12 to about 48 hours . The 
ID NO : 4 ) , GRKGK ( SEQ ID NO : 5 ) , GKKGK ( SEQ ID . resultant crosslinked polymer is purified to obtain the 35 desired peptide - crosslinked hydrogel . NO : 6 ) , GRRRGK ( SEQ ID NO : 1 ) , GKRRGK ( SEQ ID The crosslinked polymer may be used as obtained or NO : 7 ) , GKKRGK ( SEO ID NO : 8 ) , GKKKGK ( SEO ID subjected to further processing or purification . The cross 
NO : 9 ) , GRGRGK ( SEQ ID NO : 10 ) , GKGKGK ( SEQ ID linked polymer may be subjected to repeated washings ( such 
NO : 11 ) , GRRRRGK ( SEQ ID NO : 12 ) , GKRRRGK ( SEQ as with water ) to remove unreacted starting materials or 
ID NO : 13 ) , GRKRRGK ( SEQ ID NO : 14 ) , GRRKRGK 40 crosslinking by - products . subjected to centrifugation , or 
( SEQ ID NO : 15 ) , GRRRKGK ( SEQ ID NO : 16 ) , lyophilization . Additionally , other purification methods may 
GKKRRGK ( SEQ ID NO : 17 ) , GRKKRGK ( SEQ ID NO : be used such as chromatography or extractions . In some 
18 ) , GRRKKGK ( SEQ ID NO : 19 ) , GRKRKGK ( SEQ ID aspects , the dry , crosslinked polymer may be milled or 
NO : 20 ) , GKRKRGK ( SEQ ID NO : 21 ) , GGRRRGK ( SEQ crushed to obtain a fine powder . The powder may be used as 
ID NO : 22 ) , GRGRRGK ( SEQ ID NO : 23 ) , GRRGRGK 45 is or further sifted to obtain a particle size of less than 2000 
( SEQ ID NO : 24 ) , GRRRGGK ( SEQ ID NO : 25 ) , GGGR - um . In some embodiments , the powder is sifted into particles 
RGK ( SEQ ID NO : 26 ) , GRGGRGK ( SEQ ID NO : 27 ) , with a range of desired sizes , e . g . , about 30 - 75 um , 10 - 1000 
GRRGGGK ( SEQ ID NO : 28 ) , GRGRGGK ( SEQ ID NO : um , 20 - 500 um , 10 - 100 um , or about 10 , 20 , 30 , 35 , 40 , 45 , 
29 ) , GGRGRGK ( SEQ ID NO : 30 ) , GKGGGGK ( SEQ ID 50 , 55 , 60 , 65 , 70 , 75 , 80 , 85 , 90 , 100 , 200 , 300 , 400 , 500 , 
NO : 31 ) , GGKGGGK ( SEQ ID NO : 32 ) , GGGKGGK ( SEQ 50 1000 , 2000 um or any range derivable therein . 
ID NO : 33 ) , GGGGKGK ( SEQ ID NO : 34 ) , GKKGGGK 
( SEO ID NO : 35 ) , GGKKGGK ( SEO ID NO : 36 ) , GGG III . CATIONIC NANOPARTICLES AND 
KKGK ( SEQ ID NO : 37 ) , GGKGKGK ( SEQ ID NO : 38 ) , POLYMERS 
GKGKGGK ( SEQ ID NO : 39 ) , GRKGGGK ( SEQ ID NO : 
40 ) , GGRKGGK ( SEQ ID NO : 41 ) , GGGRKGK ( SEQ ID 55 In some aspects , the polymers of the present disclosure 
NO : 42 ) , GGRGKGK ( SEQ ID NO : 43 ) , GRGKGGK ( SEQ include a nanoparticle or polymer with a positive charge . A 
ID NO : 44 ) , GKRGGGK ( SEQ ID NO : 45 ) , GGKRGGK wide variety of nanoparticles or polymers may be used 
( SEQ ID NO : 46 ) , GGGKRGK ( SEQ ID NO : 47 ) , GGK - including but not limited to chitosan , poly ( ethyleneimine ) , 
GRGK ( SEQ ID NO : 48 ) , GKGRGGK ( SEQ ID NO : 49 ) , or poly ( amidoamine ) , or a poly ( aminoalkyl methacrylate ) . The 
GKKKKGK ( SEQ ID NO : 50 ) . 60 nanoparticles or polymers may comprise one or more amino 
In some aspects , the protease cleavable peptide is cross - groups which are protonated at the pH of the solution to give 
linked through carboxylic acid groups of the polymer with the nanoparticle a positive charge . In some particular 
the amine groups of the protease cleavable peptide . The embodiments , the nanoparticles comprises one more poly 
polymers that may be used in the present disclosure include ( aminoalkyl methacrylate ) . Some examples of poly ( amino 
P ( MAA - CO - NVP ) . In some embodiments , the protease 65 alkyl methacrylate ) include poly ( 2 - ( diethylaminoethyl ) 
cleavable peptide comprises a terminal lysine group . In methacrylate ) and poly ( 2 - ( dimethylaminoethyl ) methacry 
some embodiments , the cross - linked peptide is linked to the late ) . In some embodiments , the methacrylate has been 
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substituted with an amino containing alkyl chain . The amino tive . Thus , the greater identity between the siRNA and the 
group can be a primary , secondary ( e . g . alkylamine ) , or gene to be inhibited , the less likely expression of unrelated 
tertiary ( e . g . dialkylamine ) amine . The amino substituted genes will be affected . 
alkyl chain has between 1 and 12 total carbon atoms in some In addition , the size of the siRNA may be an important 
embodiments . In another embodiments , the amino substi - 5 consideration . In some embodiments , siRNA molecules that 
tuted alkyl chain has between 1 and 8 total carbon atoms . In are from 19 - 27 nucleotides in length , more preferably 20 - 25 
some embodiments , the nanoparticles may have a size from nucleotides in length , may be used as the therapeutic nucleo 
about 50 - 200 nm . tide and may be used to selectively inhibit translation of a particular gene . In some embodiments , the therapeutic 
IV . THERAPEUTIC NUCLEIC ACIDS 10 nucleotide is an antisense oligonucleotide . The antisense oligonucleotide may be less than 500 , 200 , 100 , 50 , 25 , or 
In some embodiments , a polymer as described herein may 20 nucleotides in length . In some embodiments , the thera peutic nucleotide is an miRNA that is from about 19 - 24 , or comprise or be used to deliver one or more therapeutic 19 , 20 , 21 , 22 , 23 nucleotides in length , or any range nucleic acids or polynucleotides . The therapeutic nucleic derivable therein . acid or polynucleotide may be an inhibitory nucleic acid that Within an inhibitory nucleic acid , the components of a can reduce the expression or translation of a gene or promote nucleic acid need not be of the same type or homogenous degradation of particular RNA species . In some embodi throughout ( e . g . , an inhibitory nucleic acid may comprise a 
ments , the therapeutic nucleic acid may cause or promote the nucleotide and a nucleic acid or nucleotide analog ) . Typi 
transcription or activation of a gene or gene product . For 20 cally , an inhibitory nucleic acid can form a double - stranded 
example , in some embodiments the therapeutic nucleic acid structure ; the double - stranded structure may result from two 
may comprise a promoter operably linked to a polynucle separate nucleic acids that are partially or completely 
otide that encodes a therapeutic protein ; optionally , the complementary . In certain embodiments of the present 
nucleic acid may also encode an enhancer . In some embodi - invention , the inhibitory nucleic acid may comprise only a 
ments , the therapeutic nucleic acid is from 15 - 50 , 17 - 30 , or 25 single nucleic acid ( polynucleotide ) or nucleic acid analog 
17 - 25 nucleotides in length , or any range derivable therein . and form a double - stranded structure by complementing 
Examples of an inhibitory nucleic acid that may be used with itself ( e . g . , forming a hairpin loop ) . The double 
include but are not limited to molecules targeted to an stranded structure of the inhibitory nucleic acid may com 
nucleic acid sequence , such as an small interfering RNA prise 16 - 500 or more contiguous nucleobases , including all 
( siRNA ) , short hairpin RNA ( shRNA ) , double - stranded 30 ranges derivable thereof . The inhibitory nucleic acid may 
RNA , micro RNA ( miRNA ) an antisense oligonucleotide , a comprise or consist of 17 to 35 contiguous nucleobases , 
ribozyme and molecules targeted to a gene or gene product more particularly 18 to 30 contiguous nucleobases , more 
such as an aptamer . particularly 19 to 25 nucleobases , more particularly 20 to 23 
An inhibitory nucleic acid may selectively inhibit the contiguous nucleobases , or 20 to 22 contiguous nucleobases , 35 or 21 contiguous nucleobases that can selectively hybridize transcription of a gene or prevent the translation of the gene with a complementary nucleic acid within the same transcript in a cell . An inhibitory nucleic acid may be , e . g . , sequence or with a separate mRNA of interest ( e . g . , the from 4 - 1000 or 16 - 1000 nucleotides long . In some embodi complementary sequence may be located on the same 
ments , an inhibitory nucleic acid is from 18 to 100 nucleo nucleic acid or may be present in a separate complementary 
tides long . Various therapeutic nucleotides are known in the 40 nucleic acid ) to form a double - stranded structure . In some 
art . For example , genes that may be therapeutically targeted embodiments , the RNA may be protected with a chemical 
by a nucleic acid include , e . g . , tumor necrosis factor - a . In modification to slow degradation in the body or bloodstream 
some embodiments , the therapeutic nucleic acid may be of a mammalian subject such as a human . In some embodi 
transcribed in a cell to produce a therapeutic protein in the ments , the therapeutic RNA is a locked nucleic acid ( LNA ) . 
cell . 45 siRNA can be obtained from commercial sources , natural 
Inhibitory nucleic acids are well known in the art . For sources , or can be synthesized using any of a number of 
example , siRNA , shRNA and double - stranded RNA have techniques well - known to those of ordinary skill in the art . 
been described in U . S . Pat . Nos . 6 , 506 , 559 and 6 , 573 , 099 , An inhibitory nucleic acid that can be applied in the com 
as well as in U . S . Patent Publications 2003 / 0051263 , 2003 / positions and methods of the present invention may be any 
0055020 , 2004 / 0265839 , 2002 / 0168707 , 2003 / 0159161 , 50 nucleic acid sequence that has been found by any source to 
and 2004 / 0064842 , all of which are herein incorporated by be a validated downregulator of the gene or gene product . 
reference in their entirety . In one embodiment , the siRNA molecule is at least 75 , 80 , 
In designing a nucleic acid capable of generating an RNAi 85 , or 90 % homologous , particularly at least 95 % , 99 % , or 
effect , there are several factors that need to be considered 100 % similar or identical , or any percentages in between the 
such as the nature of the siRNA , the durability of the 55 foregoing ( e . g . , the invention contemplates 75 % and greater , 
silencing effect , and the choice of delivery system . To 80 % and greater , 85 % and greater , and so on , and said ranges 
produce an RNAi effect , the siRNA that is introduced into are intended to include all whole numbers in between ) , to at 
the organism will typically contain exonic sequences . Fur - least 10 contiguous nucleotides of any of the nucleic acid 
thermore , the RNAi process is homology dependent , so the sequences encoding a target therapeutic protein . 
sequences must be carefully selected so as to maximize gene 60 The siRNA may also comprise an alteration of one or 
specificity , while minimizing the possibility of cross - inter - more nucleotides . Such alterations can include the addition 
ference between homologous , but not gene - specific of non - nucleotide material , such as to the end ( s ) of the 19 to 
sequences . Particularly the siRNA exhibits greater than 80 , 25 nucleotide RNA or internally ( at one or more nucleotides 
85 , 90 , 95 , 98 % or even 100 % identity or complementarity of the RNA ) . In certain aspects , the RNA molecule contains 
between the sequence of the siRNA and a portion of an target 65 a 3 ' - hydroxyl group . Nucleotides in the RNA molecules of 
nucleotide sequence . Sequences less than about 80 % iden - the present invention can also comprise non - standard 
tical to the target gene are typically substantially less effec - nucleotides , including non - naturally occurring nucleotides 
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or deoxyribonucleotides . The double - stranded oligonucle KOGENATE® ) ; Factor IX ; B - globin ; hemoglobin ; and the 
otide may contain a modified backbone , for example , phos - like ) ; a colony stimulating factor ( e . g . , NEUPOGEN® ( fil 
phorothioate , phosphorodithioate , or other modified back grastim ; G - CSF ) , NEULASTA® ( pegfilgrastim ) , a granulo 
bones known in the art , or may contain non - natural cyte colony stimulating factor ( G - CSF ) , a granulocyte 
internucleoside linkages . Additional modifications of siR - 5 monocyte colony stimulating factor , a macrophage colony 
NAs ( e . g . , 2 - O - methyl ribonucleotides , 2 ' - deoxy - 2 ' - fluoro stimulating factor , a megakaryocyte colony stimulating fac 
ribonucleotides , “ universal base ” nucleotides , 5 - C - methyl tor ; and the like ) ; an antigen ; an antibody ( e . g . , a monoclonal 
nucleotides , one or more phosphorothioate internucleotide antibody ) ( e . g . , RITUXAN® ( rituximab ) ; REMICADE? 
linkages , and inverted deoxyabasic residue incorporation ) ( infliximab ) ; HERCEPTIN® ( trastuzumab ) ; HUIIVIIRATM 
can be found in U . S . Publication 2004 / 0019001 and U . S . 10 ( adalimumab ) ; XOLAIR® ( omalizumab ) ; BEXXAR® ( to 
Pat . No . 6 , 673 , 611 ( each of which is incorporated by refer situmomab ) ; RAPTIVATM ( efalizumab ) ; ERBITUXTM ( ce 
ence in its entirety ) . Collectively , all such altered nucleic tuximab ) ; and the like ) , an scFv region , or an antibody 
acids or RNAs described above are referred to as modified fragment , including an antigen - binding fragment of a mono 
siRNAs . clonal antibody ; a soluble receptor ( e . g . , a TNF - a - binding 
In one embodiment , siRNA is capable of decreasing the 15 soluble receptor such as ENBREL® ( etanercept ) ; a soluble 
expression of a particular genetic product by at least 10 % , at VEGF receptor ; a soluble interleukin receptor ; a soluble y / 8 
least 20 % , at least 30 % , or at least 40 % , at least 50 % , at least T cell receptor ; and the like ) ; an enzyme ( e . g . , a - glucosi 
60 % , or at least 70 % , at least 75 % , at least 80 % , at least dase ; CERAZYME? ( imiglucarase ; B - glucocerebrosidase , 
90 % , at least 95 % or more or any ranges in between the CEREDASE® ( alglucerase ) ; an enzyme activator ( e . g . , tis 
foregoing 20 sue plasminogen activator ) ; a chemokine ( e . g . , IP - IO ; Mig ; 
Groa / IL - 8 , RANTES ; MIP - Ia ; MIP - I B ; MCP - I ; PF - 4 ; and 
V . THERAPEUTIC PROTEINS the like ) ; an angiogenic agent ( e . g . , vascular endothelial 
growth factor ( VEGF ) ; an anti - angiogenic agent ( e . g . , a 
In some embodiments , the hydrogel copolymers may soluble VEGF receptor ) ; a neuroactive peptide such as 
comprise or contain a therapeutic protein . The therapeutic 25 bradykinin , cholecystokinin , gastin , secretin , oxytocin , 
protein may be a natural and nonnatural ( e . g . , recombinant ) gonadotropin - releasing hormone , beta - endorphin , enkeph 
proteins , polypeptides , and peptides . The proteins may , by alin , substance P , somatostatin , prolactin , galanin , growth 
themselves , be incapable of passing ( or which pass only a hormone - releasing hormone , bombesin , warfarin , dynor 
fraction of the administered dose ) through the gastrointes - phin , neurotensin , motilin , thyrotropin , neuropeptide Y , 
tinal mucosa or may be susceptible to chemical cleavage by 30 luteinizing hormone , calcitonin , insulin , glucagon , vasopres 
acids or enzymes in the gastrointestinal tract or both . In sin , angiotensin II , thyrotropin - releasing hormone , vasoac 
addition to proteins , the hydrogel network also may include tive intestinal peptide , a sleep peptide , nesiritide , octreotide , 
polysaccharides , and particularly mixtures of mucopolysac teriparatide , pramlintide , and the like ; a thrombolytic agent ; 
charides , carbohydrates , lipids ; other organic compounds . an atrial natriuretic peptide ; a bone morphogenic protein ; 
For therapeutic applications , the protein may be biologically 35 thrombopoietin ; relaxin ; glial fibrillary acidic protein ; a 
active . follicle stimulating hormone ; a human alpha - 1 antitrypsin ; a 
Examples of proteins that may be comprised in a hydrogel leukemia inhibitory factor ; a transforming growth factor ; a 
copolymer of the present invention include , but are not tissue factor ; a luteinizing hormone ; a leutinizing - hormone 
limited to , synthetic , natural , or recombinant sources of : a releasing - hormone ; a macrophage activating factor , a tumor 
growth hormone ( e . g . , a somatotropin , e . g . , GENOTRO - 40 necrosis factor , a neutrophil chemotactic factor , a nerve 
PIN® , NUTROPIN , NORDITROPIN® , SAIZEN® , growth factor , a tissue inhibitor of metalloproteinases ; a 
SEROSTIM® , HUMATROPE® ) , including a human vasoactive intestinal peptide , angiogenin , angiotropin , 
growth hormone ( hGH ) , a recombinant human growth hor - fibrin ; hirudin ; a leukemia inhibitory factor ; an IL - I receptor 
mone ( rhGH ) , a bovine growth hormone , or a porcine antagonist ( e . g . , KINERET® ( anakinra ) ) ; a protease inhibi 
growth hormone ; a growth hormone - releasing hormone ; an 45 tor ; adrenocorticotropin ; a prostaglandin ; cyclosporin ; cro 
interferon ( e . g . , IFN - Y , IFN - a , IFN - B , IFN - W , IFN - T ; IFN - molyn sodium ( sodium or disodium chromoglycate ) ; van 
K ) ; an interleukin ( e . g . , IL - I ; IL - 2 , including , e . g . , PRO comycin ; desferoxamine ( DFO ) ; parathyroid hormone 
LEUKTN® ; IL - 3 , IL - 4 , IL - 5 , IL - 6 , IL - 7 , IL - 8 , IL - 9 ; and the ( PTH ) , including its fragments ; an antimicrobial ; and an 
like ) ; a growth factor ( e . g . , REGRANEX® ( beclapermin ; anti - fungal agent . Combinations , analogs , fragments , 
PDGF ) ; FIBLAST® ( trafermin ; bFGF ) ; STEMGEN® ( an - 50 mimetics or polyethylene glycol ( PEG ) - modified derivatives 
cestim ; stem cell factor ) ; a keratinocyte growth factor ; an of these compounds , or other derivatives of any of the 
acidic fibroblast growth factor , a stem cell factor , a basic above - mentioned substances may also be suitable . Also 
fibroblast growth factor , a hepatocyte growth factor ; insulin , suitable for use are fusion proteins comprising all or a 
including porcine , bovine , human , and human recombinant portion of any of the foregoing proteins . One of ordinary 
insulin ( e . g . , Novolin , Humulin , Humalog , Lantus , Ultra - 55 skill in the art , with the benefit of the present disclosure , may 
lente ) , optionally having counter ions including sodium , recognize additional drugs , including drugs other than pro 
zinc , calcium and ammonium ; an insulin - like growth factor , teins or polynucleotides , that may be useful in the compo 
including IGF - I ; a heparin , including unfractionated hepa sitions and methods of the present disclosure . Such drugs are 
rin , heparinoids , dermatans , chondroitins , low molecular still considered to be within the spirit of the present disclo 
weight heparin , very low molecular weight heparin and ultra 60 sure . 
low molecular weight heparin ; calcitonin , including salmon , 
eel , and human calcitonin ; erythropoietin ( e . g . , PROCRIT® , VI . EXAMPLES 
EPREX® , or EPOGEN® ( epoetin - a ) ; ARANESP® ( darbe 
poetin - a ) ; NEORECORMON® , EPOGIN ( epoetin - B ) ; The following examples are included to demonstrate 
and the like ) ; a blood factor ( e . g . , ACTIVASE® ( alteplase ) 65 preferred embodiments of the invention . It should be appre 
tissue plasminogen activator ; NOVOSEVEN® ( recombi - ciated by those of skill in the art that the techniques 
nant human factor VIIa ) ; Factor VIIa ; Factor VIII ( e . g . , disclosed in the examples which follow represent techniques 
19 
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discovered by the inventor to function well in the practice of After lyophilization , the polymer was milled into a fine 
the invention , and thus can be considered to constitute power by crushing with mortar and pestle . The powder was 
preferred modes for its practice . However , those of skill in sifted to the size ranges of 30 - 75 um and less than 30 um by 
the art should , in light of the present disclosure , appreciate ultraprecision ASTM sieves ( Precision Eforming , Cortland , 
that many changes can be made in the specific embodiments 5 N . Y . ) . 
which are disclosed and still obtain a like or similar result Potentiometric Titration 
without departing from the spirit and scope of the invention . To determine the MAA content of the linear polymer , a 
3 . 5 mg / ml solution of polymer in deionized water was Example 1 titrated to pH 11 . 5 using 0 . 2 N NaOH ( standardized with 
potassium hydrogen phthalate ) at 25° C . with constant Enzymatic Biodegradation of Hydrogels for Protein stirring . pH was measured with a Mettler - Toledo Sev Delivery Targeted to the Small Intestine enEasyTM ( Columbus , Ohio ) pH probe and was recorded 
when the pH reached a steady value ( + 0 . 01 pH units in three Materials consecutive measurements over 5 minutes ) . The equivalence Methacrylic acid ( MAA ) , N - vinyl - 2 - pyrrolidone ( NVP ) , 15 ™ point was used in conjunction with a charge balance to Irgacure 184® ( 1 - hydroxy - cyclohexyl - phenylketone ) , determine the amount of MAA present in each formulation . 1 - ethyl - 3 - ( 3 - dimethylaminopropyl ) carbodiimide hydro Fluorescamine Assay chloride ( EDC ) , purified pepsin from porcine gastric mucosa The fluorescamine solution was prepared fresh before ( 22500 U / mg ) and pancreatin from porcine pancreas each test by dissolving 3 mg of fluorescamine in 10 ml ( 4xUSP specifications ) , trypsin - EDTA solution ( 1x ) and 20 filtered acetone . Supernatant from the EDC - NHS reactions Na - benzoyl - L - arginine ethyl ester hydrochloride ( BAEE ) was mixed in a range of dilutions with phosphate buffered trypsin substrate , and recombinant human insulin ( 227 . 5 saline ( PBS ) and the fluorescamine solution with agitation . IU / mg ) were purchased from Sigma - Aldrich ( St . Louis , After reacting at room temperature with shaking for 15 min , Mo . ) . N - hydroxysuccinimide ( NETS ) was purchased from 200 ul of each sample was transferred in triplicate to a black Pierce Biotechnology , Inc . ( Rockford , Ill . ) . The custom 2500 96 - well plate and the fluorescence at 360 ex / 460 em was sequence oligopeptide GRRRGK ( SEQ ID NO : 1 ) was measured using a Bio - Tek SynergyTM HT multi - mode plate synthesized by CHI Scientific ( Maynard , Mass . ) . Fluores reader ( Winooski , Vt . ) , sensitivity = 85 . camine was purchased from Acros Organics ( Geel , Bel Fourier Transform Infrared Spectroscopy gium ) . All reagents were used as received . All other solvents Fourier transform infrared spectroscopy ( FTIR ) spectra and buffers were purchased from Fisher Scientific ( Waltham , 30 were obtained using a Thermo Mattson Infinity Gold spec 
Mass . ) . trometer ( Thermo Fisher Scientific Inc . , Waltham , Mass . ) . Methods The incubation buffer of degraded hydrogel samples was Synthesis and Purification exchanged with water using 30 , 000 MWCO centrifugal P ( MAA - CO - NVP ) linear polymer was synthesized by filters ( Millipore , Billerica , Mass . ) over 5 washes . Samples photoinitiated , free - radical polymerization . MAA and NVP 35 were lyophilized and then pressed in KBr ( Sigma - Aldrich ) were added at a 1 : 1 molar ratio to a 1 : 1 ( w / w ) deionized disks . For each sample , 512 scans were performed with a water and ethanol solution to yield a 1 : 3 ( w / w ) total mono resolution of 4 cm - 1 and gain of 1 . 0 , and background spectra 
mer to solvent ratio . Photoinitiator Irgacure 184 was added of a KBr blank disk was subtracted from the sample spectra . at 1 wt % with respect to total monomer weight . The mixture Scanning Electron Microscopy was homogenized by sonication then the flask was sealed 40 
with a rubber septum . The solution was purged with nitrogen Scanning electron microscopy ( SEM ) samples were pre 
for 20 minutes , then the polymerization was initiated with a pared by dusting carbon tape - covered aluminum stubs with 
Dymax Blue Wave® 200 UV point source ( Dymax , Tor lyophilized , crushed microgels . The samples were coated 
rington , Conn . ) at 100 mW / cm² intensity and allowed to with 8 - 10 nm of Pt / Pd coating using a Cressington 208 
polymerize for 30 minutes while stirring . Benchtop sputter coater ( Watford , England ) . Scanning elec Following polymerization , the linear polymer was puri 
fied from unreacted monomer by addition of 1 N hydro tron microscopy images were obtained using an FEI Quanta 
chloric acid ( HCI ) to precipitate polymer , centrifugation , 650 FEG scanning electron microscope ( Hillsboro , Oreg . ) 
and resuspension in deionized water . After three wash and a Zeiss Supra 40V scanning electron microscope ( Jena , 
cycles , the polymer solution was neutralized , frozen in 50 Germany ) . 
liquid nitrogen , and lyophilized . Degradation To synthesize the peptide - crosslinked hydrogels , linear 
P ( MAA - CO - NVP ) was dissolved in a 1 : 1 ( v / v ) water : ethanol Microgels were degraded at various trypsin concentra 
solution at a concentration of 50 mg / ml . EDC was dissolved tions in 1x phosphate buffered saline solution ( pH 7 . 4 ) , 
in ethanol at a concentration of 50 mg / ml and NHS was 55 simulated gastric fluid , simulated intestinal fluid , rat gastric 
dissolved in ethanol at a concentration of 16 mg / ml . The fluid or rat intestinal fluid . Simulated gastric fluid ( SGF ) and 
EDC and NHS solutions were added to the polymer solution ! simulated intestinal fluid ( SIF ) were prepared according to at a ratio of 6 : 3 : 1 polymer : EDC : NHS by weight . The USP 29 ( Pharmacopeia , 2006 ) . Briefly , the SGF was pre solution was mixed by vortex , then allowed to react for ~ 3 
min with shaking . The pH was raised to ~ 8 by the addition 60 pared by dissolving 2 g of sodium chloride and 3 . 2 g of 
of 1 N sodium hydroxide ( NaOH ) , and then a volume of 100 purified pepsin from porcine stomach mucosa was dissolved 
mg / ml peptide in ethanol solution was added to achieve a 2 : 1 in 800 ml deionized water . 7 ml of HC1 was added . 
weight ratio of polymer : peptide . The mixture was allowed to followed by enough water to make up to 1 L and the pH react overnight with shaking then purified by three wash 
cycles with water and centrifugation at 10 , 000xg for 5 65 ajus 6 adjusted to 1 . 2 . SIF was prepared by dissolving 6 . 8 g 
minutes . Following the washes , the polymer was frozen in monobasic potassium phosphate in 250 ml deionized water , 
liquid nitrogen and lyophilized for at least 24 hours . then 77 ml of 0 . 2 N NaOH was added while stirring . 500 ml 
21 
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additional water was added then 10 g pancreatin was mixed Cells were seeded at a density of 10 , 000 cells / well in a 
into the solution . The pH was adjusted to 6 . 8 using 0 . 2 N 96 - well plate and allowed to incubate for 24 hours prior to 
NaOH or HC1 then the solution was made up to 1 L with the experiment . Microgels were degraded in 1 . 25 or 0 . 625 
water . 5 mg / ml trypsin in PBS at concentrations ranging from 1 . 3 - 6 
Gastrointestinal fluids were harvested from Sprague Daw mg / ml . Degradation took place at 37° C . with shaking for at 
ley juvenile male rats ( 250 - 300 g ) according to a protocol least 4 hours . Trypsin was deactivated by addition of 2x 
published by Yamagata et al . with some modifications volume DMEM without phenol red containing 2 % fetal 
( Yamagata et al . , 2006 ) . Briefly , after sacrificing the rat the 10 bovine serum . Cells were incubated with degraded micro 
stomach was excised and ligated at both ends . A needle was gels for 8 hours at 37° C . and 5 % CO2 . The cytotoxic effect 
inserted to inject 5 ml of pH 1 . 2 HCl - NaCl buffer ( same as of the microgels was evaluated using a CellTiter 96® SGF minus pepsin ) and the gastric contents were collected Aqueous One Solution Cell Proliferation MTS Assay ( Pro in a 50 ml centrifuge tube . Similarly , a ~ 20 cm section of the 15 mega , Madison , Wis . ) . MTS assay was added to the wells upper small intestine was cannulated and flushed twice with 15 and incubated for 90 minutes at the same conditions before 10 ml cold PBS ( 1x , pH 7 . 4 ) . The fluid was collected as absorbance measurements were made at 490 nm using a intestinal fluid in a 50 ml centrifuge tube . Both the harvested 
fluids were centrifuged at 3 , 200xg , 4° C . , for 15 min to Bio - Tek SynergyTM HT multi - mode plate reader ( Winooski , 
separate solids from the fluids . The supernatants were 20 Vt . ) . Cytotoxicity is reported as ' relative cell proliferation ' , 
retained as rat gastric fluid and rat intestinal fluid , respec or normalization of the assay absorbance values to the 
tively . Fluids were stored at - 20° C . until use . average assay absorbance for cells incubated in only culture 
Degradation was measured by relative turbidity of the media . 
solutions over time , as reported by Klinger and Landfester , 25 Insulin Loading 
2012 . Microgels were suspended in trypsin solutions of Microgels were loaded by equilibrium partitioning post 
varying concentration , PBS , SGF , SIF , or rat gastrointestinal synthesis with recombinant human insulin . Microgels were 
fluids at various concentrations . 100 ul of each solution was incubated at 37° C . for 4 hours in a 0 . 5 mg / mL insulin added to a 96 - well plate in triplicate , and the absorbance was 30 solution of pH ~ 5 . 5 at a ratio of 7 : 1 microgel : therapeutic by measured at 500 nm in 5 minute intervals over 90 minutes weight . The microgels were collected by centrifugation at using a Bio - Tek SynergyTM HT multi - mode plate reader 10 , 000xg for 5 minutes then collapsed by resuspension in ( Winooski , Vt . ) . The temperature was controlled at 37° C . 
and the plate underwent shaking for 3 seconds before each 0 . 5 N HCl . Microgels were separated from supernatant by 
measurement . 35 centrifugation at 10 , 000xg for 5 minutes . The loaded micro 
Activity of the trypsin following incubation with particles gels were lyophilized and stored at - 20° C . for further gens were lyopi 
and deactivation methods including addition of serum - con studies . Protein loading was evaluated with a MicroBCA 
taining cell culture media or 5 minutes incubation at 60° C . , assay protein quantification assay ( Pierce - Thermo , Rock 
70° C . , or 80° C . , was evaluated using a trypsin activity 
assay adapted from the protocol by Yanes et al . , 2007 . Results and Discussion 
Briefly , degradation supernatant was combined with 1 Synthesis , purification and lyophilization of the uncross mg / ml BAEE in PBS at a 1 : 9 sample : BAEE ratio by 45 linked P ( MAA - CO - NVP ) yielded white , fluffy polymer . Due volume . Immediately after addition of the BASE , absor to the phase transition of MAA from hydrophobic to hydro bance at 253 nm was measured at the minimum interval philic above pH ~ 5 , adjusting the pH of the solution to ( typically 40 - 50 seconds ) for 5 minutes using a Bio - Tek 
SynergyTM HT multi - mode plate reader ( Winooski , Vt . ) . neutral prior to freeze drying facilitated the solubilization of 
In Vitro Cytotoxicity Study 50 the dried polymer into aqueous solution . Potentiometric 
L929 and RAW 264 . 7 cell lines were obtained from titration was used to determine that the linear polymer was 
American Type Culture Collection ( ATCC . Rockwell . Md . ) . approximately 45 mol % or 39 wt % MAA . 
All cell lines were cultured in Dulbecco ' s modified Eagle Scheme 1 shows the mechanism of the EDC - NHS cross 
medium ( DMEM ) ( Mediatech , Herndon , Va . ) supplemented 55 linking reaction with the linear P ( MAA - CO - NVP ) . Upon 
with 10 % heat - inactivated HyCloneTM Fetal Bovine Serum , solubilization of the polymer in the ethanol - water solution , 
USDA Tested ( Fisher Scientific ) , 1 % 200 mM L - glutamine the pH was adjusted to ~ 5 to favor the activation of the 
solution ( Mediatech ) , 100 U / ml penicillin , and 100 ug / ml carboxylic acid groups by EDC and increase the stability of 
streptomycin ( Mediatech ) . Cytotoxicity studies were per - 60 the active ester intermediate ( Hermanson , 1996 ) . EDC was 
formed using DMEM without phenol red supplemented with added at a molar ratio of 1 : 2 to the MAA groups on the linear 
2 % heat - inactivated HyCloneTM Fetal Bovine Serum , USDA chains , and NHS was added at a molar ratio of 1 : 1 . 8 to the 
Tested ( Fisher Scientific ) , 1 % non - essential amino acids EDC . Upon addition of the EDC and NHS the solution 
( Mediatech ) , 100 U / ml penicillin , and 100 ug / ml strepto - as became turbid but no precipitation was evident . Both the 
mycin ( Mediatech ) . Cells were incubated at 37° C . in a 5 % EDC and NHS were dissolved in ethanol to limit instability 
CO2 environment . due to hydrolysis while maintaining polymer solubility . 
40 ford , Ill . ) . 
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Scheme 1 . Peptide crosslinking reaction scheme . Carboxylic acid groups on the poly ( methacrylic acid - co - N - vinylpyrrolidone ) 
linear polymer are activated by EDC , then react with at least two of the five primary amine groups on the GRRRGK ( SEQ ID NO : 1 ) 
peptide to form a crosslinked hydrogel network . 
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After activation of the carboxylic acid groups , the pH was to the theoretical maximum of activated carboxyl groups . 
raised to ~ 7 - 8 to facilitate attack on the primary amines of Upon addition of the peptide solution the mixture was 
the oligopeptide ( Hermanson , 1996 ) . Various polymer : EDC : immediately turbid and precipitation of crosslinked polymer 
NHS : peptide weight ratios were tested to maximize peptide was evident . After reacting for at least 8 hours the cross 
incorporation . All formulations with peptide content below 60 linked polymer typically resembled an amorphous hydrogel . 
a polymer : peptide ratio of ~ 3 : 1 failed to produce hydrogels . Following washes and lyophilization the hydrogel 
A best performing formulation of solvents , polymer , and appeared as fluffy white chunks . The dried hydrogel was 
EDC - NHS based on reaction efficiency and reproducibility easily crushed into a powder consisting of particles < 30 um 
was an ethanol - water mixture with a polymer : EDC : NHS : in size , shown in the SEM micrograph in FIGS . 1A - B . 
peptide weight ratio of 20 : 10 : 3 . 3 : 10 . 65 Fluorescamine Assay 
The peptide was added at a molar ratio of 1 : 3 . 6 relative to The fluorescamine assay was used to quantify the amount 
the EDC ; the free amine groups were in 1 . 4x excess relative of peptide remaining in solution following the EDC - NHS 




crosslinking reaction . The fluorescamine reagent is com - was sought . Turbidity is commonly used to evaluate the 
monly used as a fluorometric assay of free amine content , temperature - dependent phase transition and swelling of ther 
which can be used as a measurement of protein or peptide moresponsive polymers such as poly ( N - isopropyl acrylam 
content ( Bohlen et al . , 1973 ) . A known concentration of ide ) ( Xu et al . , 2007 ; Qiu et al . , 2007 ) , and Klinger and 
peptide was used as the standard to obtain quantitative 5 Landfester , 2011 showed that for photo - degradable poly 
results . Assay of the reaction conditions without peptide ( methyl methacrylate ) particles the change in hydrodynamic 
showed no background fluorescence as expected . radius as a function of swelling and degradation correlated 
The fluorescamine assay was used to measure the reaction well with the decrease in turbidity . 
efficiency as a function of the ratio of linear polymer to Per the second report by Klinger and Landfester , 2012 , 
peptide . The reaction efficiencies of a 1 : 1 and a 2 : 1 polymer : 10 change in relative turbidity could be used to evaluate deg 
peptide weight ratio were compared by quantifying the radation as a function of time . Klinger and Landfester 
peptide remaining in solution at the completion of the attribute the reduction in turbidity during degradation to a 
reaction . In the case of the 1 : 1 ratio , 16 . 6 wt % of the peptide loosening of the network , resulting in greater swelling of the 
remained in solution . However , at the 2 : 1 ratio only 1 . 8 wt gel therefore less contrast between the refractive indices of 
% of the peptide remained in solution . All subsequent 15 the solvent and the polymer Klinger and Landfester , 2011 . 
reactions were carried out at the 2 : 1 polymer : peptide weight Mathematically , it can be explained by the following equa 
ratio . tion for turbidity as described by Lechner , 2005 : 
FTIR Spectroscopy 
FTIR spectroscopy was used to evaluate the composition 
of the peptide - crosslinked microgels before and after deg - 20 Qext 3 
radation . As shown in FIG . 2 , the characteristic bands of the 2d 
carboxylic groups of MAA are present at 2900 cm - and 
1560 cm and the bands of carbonyl groups in MAA and where o is the volume fraction of the particles , Rext is the NVP are present at 1640 cm . Characteristic bands of the Mie extinction efficiency , and d is the particle diameter . In peptide that can be attributed to CN and NH , stretching 25 m - most cases , it is useful to make the substitution appear at 1140 cm - 1 and 800 cm - ? ( Kolev , T . , 2006 ) . 
Incorporation of the peptide into the crosslinked gel was 
confirmed by the presence of these bands . FIG . 3 shows that 
there was no discernable difference between the spectra of Q = = 
intact and degraded microgels . However , upon exposure to 30 
the low pH of the SGF the characteristic carbonyl bands 
were shifted from 1680 cm - 1 to 1725 cm - 1 and 1640 cm - 1 where c = mass concentration of the particles and p - density 
compared to that in the neutral pH SIF , indicating the of the particles . 
presence of hydrogen bonding within the microgels at low lext is a function of the ratio of refractive indices of the 
pH conditions . 35 particles and solvent , n , / no , as well as the size of the 
Degradation particles , and decreases as the ratio n , / n , or the particle 
The peptide crosslink was designed with multiple arginine diameter decreases . 
and lysine residues so that it would be targeted specifically . Therefore , it was hypothesized that as the enzymatically 
by the enzyme trypsin , prevalent in the small intestine but degradable microgels swelled then degraded into smaller 
would not be susceptible to attack by the enzyme pepsin in 40 particles and eventually into linear polymer chains with 
the stomach ( Vlieghe et al . , 2010 ) . Trypsin is known to minimal contrast between refractive indices of the polymer 
cleave at the C - terminal of arginine and lysine residues and solvent , the turbidity should decrease over time in 
( Olsen , 2004 ) and each peptide link has four possible correlation with the extent of degradation . Absorbance of the 
cleavage sites as shown in Scheme 1 . degrading microgel solutions was measured at an arbitrary 
First , degradation of the microgels was assessed visually 45 value of 500 nm as the absorbance of the solutions plateaued 
in SGF containing the enzyme pepsin , SIF containing the in the 300 - 800 nm range . The absorbance value was first 
enzyme trypsin , or PBS . The hydrogel in trypsin solution converted to percent transmittance using the following equa 
was no longer visible after only 30 minutes . However , the tion 
hydrogels in the pepsin and PBS solutions were still easily 1 = 10 ( 2 - 4 ) discernable after 4 hours of incubation . 
SEM was used to visualize the morphology of partially then to turbidity using the equation 
degraded microgels , shown in FIGS . 4A - F . The microgels 
were incubated in buffers for 90 minutes then the degraded 
samples were flash frozen in liquid nitrogen and lyophilized . 
A microgel in SGF is shown in FIG . 4A and FIG . 4D and a 55 
microgel in PBS is shown in FIG . 4C and FIG . 4F ; in both 
cases , a macroporous structure caused by lyophilization is where I , is transmittance of the sample at time t and I . is easily discernable and reflects the structural integrity of the transmittance of pure solvent . Finally , relative turbidity , hydrogel . A microgel in SIF is shown in FIG . 4B and FIG . 
4E , and following incubation with enzyme the hydrogel 60 which permits better comparison between samples that vary in particle size , was calculated as structure appears to be collapsed rather than porous , con 
firming the loss of structural integrity due to degradation of 
the crosslinks . T ( 1 ) As the method of synthesis yielded amorphous hydrogel 
pieces on the order of millimeters in size , gravimetric 65 
analysis of degradation over time was impractical to 
execute . Thus , a different method of assessing degradation and plotted as a function of time . 
O 
T ( t ) = - 
Tret = ( t = 0 ) 
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As hypothesized , upon incubation with trypsin solutions turbidity steadily decreased across the 4 hour incubation 
of various concentrations the turbidity of the microgel period , arriving at a final reduction in relative turbidity of 
solutions decreased over 90 minutes , shown in FIG . 5 . The 85 % . Though the degradation was not as rapid as the trypsin 
mass concentration of particles was held constant , therefore solutions , the intestinal fluid was significantly diluted during 
the trypsin concentration was directly related to decrease in 5 harvest so it is quite possible that the physiological trypsin 
relative turbidity ; the higher the trypsin content , the greater concentration is actually higher and able cause more rapid 
the extent of degradation after 90 minutes . Interestingly , degradation in vivo . These results are extremely promising 
when microgels were incubated in low trypsin concentra - for oral drug delivery applications , as the degradation is 
tions or in PBS there was an initial increase in turbidity specific to intestinal fluid and occurs on a timescale relevant 
followed by decreasing turbidity or a plateau in the case of 10 to small intestinal residence time ( Davis et al . , 1986 ) . 
PBS . As the particles are expected to swell in PBS and swell The activity of trypsin was evaluated by spectrophoto 
then degrade in the trypsin , this behavior is incongruent with metric measurement using BAEE , an arginine - containing 
the explanation set forth by Klinger and Landfesterm 2011 , substrate that absorbs at 253 nm upon cleavage by trypsin . 
in which turbidity is expected to decrease with swelling of Trypsin activity is correlated to rate of absorbance increase 
the particles . Looking at the relationship for turbidity estab - 15 over the initial 5 minutes of the reaction , and the absorbance 
lished by Lechner in Eq . 1 , turbidity is dependent upon reaches a plateau when the cleavage reaction is complete ) . 
particle size and concentration as well as the contrast Due to the scale of the degradation reactions , the assay was 
between polymer and solvent refractive indices . This initial adapted and optimized for a 96 - well assay format on the 
increase in turbidity may be attributed to the change in size microliter - scale as opposed to the previously reported mil 
of the particles due to swelling and bulk degradation . The 20 liliter - scale protocols ( Yanes et al . , 2007 ) . 
imbibition of solvent by the swollen particles likely reduced Using the optimized reaction conditions for the 96 - well 
the refractive index of the particles but was not sufficient to assay , various degradation and trypsin deactivation condi 
overcome the effect of the particle size contribution to tions were evaluated to determine the trypsin activity as a 
turbidity as the microgels degraded into smaller pieces via function of microgel concentration and subsequent deacti 
bulk degradation . At approximately 30 minutes the particles 25 vation method . The trypsin deactivation was carried out to 
in PBS reached equilibrium swelling , at which point the ensure the trypsin would not negatively impact adherent cell 
relative turbidity became constant . The point at which the lines during in vitro characterization studies . Microgel con 
degradation by trypsin was sufficient enough to overcome centrations of 0 , 1 . 5 , 3 , and 6 mg / ml were incubated with 0 . 6 
the effect of particle size and reduce the relative turbidity mg / ml trypsin at 37° C . for 90 minutes . 
was dependent upon the concentration of trypsin , with the 30 As shown in FIG . 7 , the samples without deactivation had 
transition to decreasing relative turbidity happening sooner a strong linear correlation in absorbance increase over time ; 
at higher trypsin concentrations where degradation is pre - as previously reported , the greater the slope of this linear fit 
sumably happening on a faster timescale and surface deg the higher the trypsin activity ( Schwert and Takenaka , 
radation is controlling . 1955 ) . Slope and R - values of the linear fit for each particle 
Drug release can be affected by a combination of reaction 35 concentration are shown in Table S . 1 , and it can be seen that 
and diffusion phenomena , and drug release has been mod trypsin activity on the BAEE substrate is reduced as micro 
eled for various systems . Lao et al . , 2008 modeled tri - phasic gel concentration increases . This confirmed the enzymatic 
drug release from bulk - degrading polymer blends by devel - reaction between the trypsin and the peptide crosslinks 
oping a three - step sequence to describe the diffusion of drug . within the microgels . 
Himmelstein and coworkers ( Thombre and Himmel stein , 40 In a subsequent study , microgel concentration was held 
1985 ; Joshi and Himmelstein , 1991 ) developed models to constant at 2 mg / ml while trypsin concentration was varied 
describe the release of a model drug from poly ( orthoester ) from 0 . 0375 - 0 . 6 mg / ml . As seen in FIG . 8A , the lowest two 
during simultaneous diffusion - reaction transport due to acid - concentrations of trypsin solutions containing no microgels 
catalyzed hydrolysis . Others have modeled polymer degra - had final absorbance values below that of the control , PBS , 
dation and drug release as a function of combined diffusion 45 indicating no appreciable trypsin activity . Therefore , it was 
and enzyme - kinetics . For example , Anseth and coworkers expected that little degradation would occur at those con 
( Rice et al . , 2006 ) modeled the degradation of lipase - centrations . As expected , samples tested after 90 minutes of 
catalyzed hydrolysis of hydrogels for tissue engineering incubation of these trypsin solutions with microgels quickly 
applications , and Cheng et al . , 2011 modeled the release of reached a plateau during the activity assay , shown in FIG . 
a small molecule from enzymatically - degradable gelatin . 50 8B , confirming quenched trypsin activity . Trypsin concen 
The degradation of the microgels during incubation with trations of 0 . 3 and 0 . 6 mg / ml were sufficient to maintain 
the rat gastrointestinal fluids versus trypsin solutions is enough trypsin activity to degrade peptide crosslinks in the 
shown in FIG . 6 . As in the previous case , the relative microgels , as indicated by increasing absorbance over the 5 
turbidity of the microgels in PBS solution increased for the minute assay period . Further narrowing the range of trypsin 
first ~ 30 minutes then was relatively constant over the 55 concentrations , the activity assay was used to determine that 
remainder of the 4 hour incubation period . Relative turbidity trypsin concentrations down to 0 . 2 mg / ml maintained excess 
of particle solutions at both the 0 . 3 and 0 . 6 mg /ml trypsin activity during degradation with microgels . FIG . 8C dem 
concentrations decreased to well below 10 % by the end of onstrated that the trypsin activity was effectively quenched 
the 4 hour incubation , with the solution with higher trypsin by incubation at 70° C . for 5 minutes . 
concentration reaching a lower value in a shorter period of 60 As shown above , the trypsin activity was entirely 
time . The relative turbidity of the particles incubated with quenched by reaction with proteins in the DMEM containing 
gastric fluid was approximately constant for nearly 3 hours , serum as indicated by negligible increase in absorbance 
at which time the evaporation of the fluid started to have an from BAEE cleavage , shown in FIG . 7 . This was desirable 
effect on the enzyme concentration , the absorbance path for subsequent exposure to cells in later studies , since 
length , or both , and turbidity decreased slightly . Most 65 trypsin can have a negative impact on cell metabolism and 
encouraging , though , was the significant degradation of the behavior . However , the microgel concentration was signifi 
microgels incubated in rat intestinal fluid . The relative cantly diluted upon addition of the DMEM , necessitating 
masso - massf — * 100 ( 7 ) 
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highly concentrated particle solutions during degradation to - continued 
achieve the desired final concentration . 
According to the literature , a 5 minute incubation period Weight Loading Efficiency = = masso – massf + massp 
in temperatures ranging from 60 - 80° C . should also be 
sufficient to deactivate the trypsin ( Pace , 1930 ) . Following 5 
the 90 minute degradation period in 0 . 6 mg / ml trypsin , The overall loading efficiency of the insulin after collapse 
samples at each microgel concentration were incubated at of the particles , shown in FIG . 11 , was ~ 41 % and the weight 
60 , 70 , or 80° C . for 5 minutes . The BAEE trypsin activity loading efficiency of insulin was 5 . 6 % . These loading and 
assay indicated that samples incubated at 60° C . still con weight efficiencies were comparable to those reported for 
tained some trypsin activity , as evidenced by the increase in nced by the increase in 10 similar hydrogel systems with large proteins ( Wong et al . , 
absorbance over time shown in FIG . 9A . However , the rate 2014 ; Liang et al . , 2014 ) . 
of increase was still smaller than that of samples with active As shown by the data above , synthesis of the linear polymer and crosslinked hydrogels was greatly affected by trypsin , with values ranging from only 16 - 26 a . u . / min com pH of the respective reaction solutions . The crosslinking pared to 64 - 80 a . u . / min . Samples incubated at higher tem 15 reaction was most successful using linear polymer peratures of 70° C . and 80° C . for 5 minutes had negligible lyophilized at pH 8 in a two - part EDC - NHS linking reaction 
trypsin activity , shown by no absorbance increase in FIG . transitioned from pH 5 to pH 8 . Incorporation of the peptide 
9B . This method of deactivation was advantageous to the was consistently above 97 % as determined by fluorescamine 
addition of DMEM , as microgels remained concentrated , assay of the peptide remaining in solution , and incorporation 
requiring less starting material to reach the desired final 20 was verified by IR spectra . 
concentration . Proteolytic degradation of the peptide crosslinks upon 
Cytotoxicity incubation with trypsin solutions , SIF , and rat intestinal fluid 
Cytotoxicity studies were performed with various micro was demonstrated by reduced relative turbidity as a function 
gel concentrations to find the maximum concentration that of time and trypsin concentration . In contrast , relative tur 
L929 murine fibroblast and RAW 264 . 7 murine macrophage 25 bidity of the microgel solutions remained constant upon 
cells could tolerate without disruption to metabolic activity . incubation in PBS , SGF , and rat gastric fluid , verifying that 
Microgels were incubated in 1 . 2 or 0 . 6 mg /ml trypsin the microgels were not susceptible to degradation by the 
solution for at least 4 hours to ensure degradation of the gastric enzyme pepsin . The degradable microgels induced 
microgels ; PBS buffer was used as a control . As trypsin can negligible cytotoxic effects , even at high concentration , in 
have negative effects on cell function ( Kaplan and Bona , 30 both the degraded and nondegraded states . These studies 
1974 ) , particularly the antigen - presenting ability of macro confirm the biodegradable behavior of the peptide cross 
phages ( Unanue , 1984 ) , the trypsin was deactivated by the linked hydrogel is highly suitable for intestinal delivery 
addition of excess cell media containing serum prior to applications . 
exposure to cells . Cells were incubated with degraded The P ( MAA - CO - NVP ) polymer backbone demonstrated 
microgel solutions for 8 hours to assess cytotoxic effect . 35 pH responsive behavior , swelling at neutral conditions and 
FIG . 10A and FIG . 10B show L929 and RAW 264 . 7 cell collapsing at low pH gastric conditions . The microgels were 
proliferation , respectively , relative to that of cells incubated able to efficiently load the therapeutic protein insulin and 
in normal media without microgels . Relative proliferation retain the loaded protein in low pH conditions . These data 
greater than 80 % is considered acceptable in our evaluation . show that the enzymatic response , relevant degradation 
For all conditions and concentrations , cell proliferation is 40 timescale , and high biocompatibility of this biodegradable 
greater than 80 % relative to the cells incubated in normal microgel system . Based on these data , this microgel system 
media . It was concluded that these degradation conditions may be effectively used as a vehicle for oral delivery of 
and degradation products at these tested concentrations therapeutics , including relatively delicate proteins such as , 
posed minimal cytotoxic effect to these two cell lines . e . g . , insulin . 
Insulin Loading 45 
Insulin , a small therapeutic protein ( ~ 5 . 8 kDa ) , was Example 2 
chosen as a model therapeutic in loading and release studies 
since an oral delivery method for insulin has been widely Biodegradable Microencapsulated Nanogels for 
investigated ( Lowman et al . , 1999 ; Kavimandan et al . , 2006 ; Orally Delivered siRNA 
Peppas and Kavimandan , 2006 ; Nakamura et al . , 2004 ) . 50 
Protein concentration was measured in the supernatant fol Materials 
lowing the 4 hour loading period with microgels , then again Chemicals 
in the supernatant following collapse of the microgels in 0 . 5 Methacrylic acid ( MAA ) , N - vinyl pyrrolidone ( NVP ) , 
N HCl . Protein that was likely surface loaded was lost and Irgacure 184® ( 1 - hydroxy - cyclohexyl - phenylketone ) 
during the HC1 wash . A significant amount of protein 55 were obtained from Sigma - Aldrich ( St . Louis , Mo . ) . 1 - ethyl 
remained loaded following the HCl wash , indicating loading 3 - ( 3 - dimethylaminopropyl ) carbodiimide hydrochloride 
of the protein within collapsed microgels as opposed to ( EDC ) was obtained from Sigma Aldrich . N - hydroxysuc 
surface loading . Loading efficiencies were calculated as cinimide ( NETS ) was obtained from Pierce Biotechnology , 
follows , where co is the initial protein concentration , ofis the Inc . ( Rockford , ill . ) . The custom sequence oligopeptide 
final protein concentration , mass , is the initial mass of 60 GRRRGK ( SEQ ID NO : 1 ) was synthesized by CHI Sci 
protein in solution , massy is the final mass of protein in entific ( Maynard , Mass . ) . All reagents were used as 
solution , and mass , is the mass of polymer in solution : received . Purified pepsin from porcine gastric mucosa 
( > 2500 U / mg ) , pancreatin from porcine pancreas ( 4xUSP 
specifications ) , Trypsin - EDTA solution ( 1x ) and Na - ben 
Loading Efficiency = “ Y * 100 ( 6 ) 65 zoyl - L - arginine ethyl ester hydrochloride ( BAEE ) trypsin 
substrate were obtained from Sigma - Aldrich . 4 - Chloro - 7 
nitrobenzofurazan ( NBD - C1 , 98 % ) was obtained from Acros 
CO 
US 9 , 937 , 256 B2 
32 
Organics ( Geel , Belgium ) . All other solvents and buffers N . Y . ) . Transfection studies were completed in OptiMEM® 
were purchased from Fisher Scientific ( Waltham , Mass . ) . reduced serum media ( no phenol red ) . Cells were incubated 
Polycationic 2 - ( diethylamino ) ethyl methacrylate - based at 37° C . in a 5 % CO2 environment . 
nanogels ( ~ 100 nm diameter ) were synthesized by Forbes et 
al , 2013 and tagged with a fluorescent molecule , NBD - C1 , 5 Cells were seeded at a density of 10 , 000 cells / well in a 
by Forbes et al . , 2014 . 96 - well plate and allowed to incubate for 24 hours prior to Synthesis and Purification the experiment . Microgels were degraded in 0 . 3 - 1 . 25 mg / ml 
Synthesis of Linear Polymer : trypsin in phosphate buffered saline ( PBS ) at concentrations P ( MAA - CO - NVP ) linear polymer was synthesized by ranging from 1 . 3 - 6 mg / ml . Degradation took place at 37° C . photoinitiated , free - radical polymerization . MAA and NVP 10 with shaking for 90 minutes or 4 hours . Trypsin was were added at a 1 : 1 molar ratio to a 1 : 1 ( w / w ) deionized deactivated by addition of 2x volume DMEM without water and ethanol solution to yield a 1 : 3 ( w / w ) total mono phenol red containing 2 % fetal bovine serum or by incuba mer to solvent ratio . Photoinitiator Irgacure 184 was added 
at 1 wt % with respect to total monomer weight . tion at 70° C . for 5 minutes . Cells were incubated with 
The mixture was homogenized by sonication then the 15 on the 15 degraded microgels for 18 hours at 37° C . and 5 % CO2 . The 
round bottom flask was sealed with a rubber septum . The cytotoxic effect of the microgels was evaluated using a 
solution was purged with nitrogen for 20 minutes , then the CellTiter 96® Aqueous One Solution Cell Proliferation 
reaction was initiated with a Dymax Blue Wave® 200 UV MTS Assay or a Cyto Tox - ONETM Homogeneous Membrane 
point source ( Dymax , Torrington , Conn . ) at 100 mW / cm2 Integrity Assay ( Promega , Madison , Wis . ) . In the case of the 
intensity and allowed to polymerize for 30 minutes while 20 proliferation assay , MTS was added to the wells and incu 
stirring bated for 90 minutes at the same conditions before absor 
Following polymerization , the linear polymer was puri - bance measurements were made at 490 nm using a Bio - Tek 
fied from unreacted monomer by addition of 1 N hydro - SynergyTM HT multi - mode plate reader ( Winooski , Vt . ) . In 
chloric acid ( HCI ) to precipitate polymer , centrifugation , the case of the membrane integrity assay , 50 ul of the cell 
and resuspension in deionized water . After 3 wash cycles , 25 media from each well was combined with 50 ul of the assay 
the polymer solution was frozen in liquid nitrogen ( LN ) and solution in a black - walled 96 - well plate , incubated at room 
lyophilized for at least 24 hours . temp for 10 minutes , then the fluorescence was measured at 
Synthesis of Peptide Crosslinked Gels : 530 / 560 ( sensitivity = 60 ) using a Bio - Tek SynergyTM HT 
Linear P ( MAA - CO - NVP ) was dissolved in a 1 : 1 ( v / v ) multi - mode plate reader ( Winooski , Vt . ) . Cytotoxicity is 
water : ethanol solution at a concentration of 50 mg / ml . EDC 30 reported as “ relative cell proliferation ' using the MTS assay 
was dissolved in ethanol at a concentration of 50 mg / ml and and “ percent viability ' using the membrane integrity assay . 
NHS was dissolved in ethanol at a concentration of 16 siRNA Loading : 
mg / ml . The EDC and NHS solutions were added to the Microgels containing NBD - labeled nanogels were loaded 
polymer solution at a ratio of 6 : 3 : 1 polymer : EDC : NHS by by equilibrium partitioning post - synthesis with Silencer® 
weight . The solution was mixed by vortex briefly , then 35 Select Negative Control No . 1 ( Life Technologies ) , AllStars 
allowed to react for ~ 3 min with shaking . Polycationic Mm / Rn Cell Death Control siRNA , AllStars Hs Cell Death 
nanoparticles in a 10 mg / ml solution in ethanol were added Control siRNA , Negative Control siRNA ( Qiagen , Hilden , 
at 10 wt % relative to the P ( MAA - CO - NVP ) and the solution Germany ) , or fluorescently labeled DyLight 647 - labeled 
was briefly mixed by vortex . The pH was raised to m8 by the siRNA ( Sense : DY647 - UAAGGCUAUGAAGA 
addition of 1 N sodium hydroxide ( NaOH ) , and then a 40 GAUACUU ( SEQ ID NO : 51 ) ; Thermo Scientific , Lafay 
volume of 100 mg / ml peptide in ethanol solution was added ette , Colo . ) . Microgels were incubated at a concentration of 
to achieve a 2 : 1 weight ratio of polymer : peptide . The 12 mg / ml at 37° C . for 1 . 5 hours in a 400 nM or 100 nM 
mixture was allowed to react overnight with shaking then siRNA solution in nuclease - free PBS at pH ~ 5 . 5 . Nuclease 
purified by 3 wash cycles with water and centrifugation at free 10xPBS was prepared by dissolving sodium chloride , 
10 , 000xg for 5 minutes . Following the washes , the polymer 45 potassium chloride , monobasic potassium phosphate , and 
was frozen in LN , and lyophilized for at least 24 hours . sodium phosphate dibasic heptahydrate in water , treating 
After lyophilization , the polymer was milled into a fine with 0 . 1 % v / v diethylpyrocarbonate ( DEPC ) overnight , and 
power by crushing with mortar and pestle . The powder was then autoclaving to remove DEPC . The microgels were 
sifted to the size ranges of 30 - 75 um and less than 30 um by collected by centrifugation at 10 , 000xg for 5 minutes . The 
ultraprecision ASTM sieves ( Precision Eforming , Cortland , 50 loaded microgels were stored at - 20° C . until further studies . 
N . Y . ) . siRNA loading was evaluated by Quant - iTTM RiboGreen® 
Cell Culture : RNA Assay Kit ( Invitrogen ) . 
Human colon adenocarcinoma Caco - 2 , murine fibroblast Microgel Degradation : 
L929 , and murine macrophage RAW 264 . 7 cells obtained Microgels were degraded at various trypsin concentra 
from American Type Culture Collection ( ATCC , Rockwell , 55 tions ranging from 0 . 2 - 1 . 2 mg / ml in 1x phosphate buffered 
Md . ) . All cell lines were cultured in Dulbecco ' s modified saline solution ( pH 7 . 4 ) , simulated gastric fluid , simulated 
Eagle medium ( DMEM ) ( Mediatech , Herndon , Va . ) supple - intestinal fluid , rat gastric fluid or rat intestinal fluid . 
mented with 10 % heat - inactivated HyCloneTM Fetal Bovine Simulated gastric fluid ( SGF ) and simulated intestinal 
Serum , USDA Tested ( Fisher Scientific ) , 1 % 200 mM L - glu - fluid ( SIF ) were prepared according to USP 29 ( Pharmaco 
tamine solution ( Mediatech ) , 100 U / ml penicillin , and 100 60 peia , 2006 ) . Briefly , SGF was prepared by dissolving 2 g of 
ug / ml streptomycin ( Mediatech ) . Cytotoxicity studies were sodium chloride and 3 . 2 g of purified pepsin from porcine 
performed using DMEM without phenol red supplemented stomach mucosa was dissolved in 800 ml deionized water . 
with 2 % heat - inactivated HyCloneTM Fetal Bovine Serum , 7 ml of HCl was added , followed by enough water to make 
USDA Tested ( Fisher Scientific ) , 1 % non - essential amino up to 1 L and the pH adjusted to 1 . 2 . SIF was prepared by 
acids ( Mediatech ) , 100 U / ml penicillin , and 100 ug / ml 65 dissolving 6 . 8 g monobasic potassium phosphate in 250 ml 
streptomycin ( Mediatech ) or OptiMEM® reduced serum deionized water , then 77 ml of 0 . 2 N NaOH was added while 
media ( no phenol red ) ( Life Technologies , Grand Island , stirring . 500 ml additional water was added then 10 g 
33 
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pancreatin was mixed into the solution . The pH was adjusted imaged with a Typhoon 9500 fluorescent imager using the 
to 6 . 8 using 0 . 2 N NaOH or HC1 then the solution was made SYBR green II filter , 50 um pixel size , 500 pmt . ( GE Life 
up to 1 L with water . Sciences , Pittsburgh , Pa . ) . 
Gastrointestinal fluids were harvested from Sprague Daw Confocal Microscopy : 
ley juvenile male rats ( 250 - 300 g ) according to a protocol 5 Microgels were fluorescently labeled with TAMRA - ca 
published by Yamagata et al . with some modifications daverine ( Biotium ) via EDC - NHS reaction . Briefly , 15 mg 
( Yamagata et al . , 2006 ) . Briefly , after sacrificing the rat the microgels were mixed with 1 . 25 mg of EDC and 1 . 25 mg 
stomach was excised and ligated at both ends . A needle was NHS in 0 . 1 M MES buffer at pH 4 . 7 . After a ~ 3 minute 
inserted to inject 5 ml of pH 1 . 2 HCl - NaCl buffer ( same as incubation period at room temperature , 15 ul of 0 . 5 mg / ml 
SGF minus pepsin ) and the gastric contents were collected 10 TAMRA - cadaverine solution was added and allowed to 
in a 50 ml centrifuge tube . Similarly , a ~ 20 cm section of the react for 2 hours at room temperature . The polymer was 
upper small intestine was cannulated and flushed twice with washed 5x by centrifugation at 10 , 000xg for 5 minutes and 
10 ml cold PBS ( 1x , pH 7 . 4 ) . The fluid was collected as resuspension in 1 ml DI water to remove unreacted fluoro 
intestinal fluid in a 50 ml centrifuge tube . Both the harvested phore . The final wash was left overnight to allow the 
fluids were centrifuged at 3 , 200xg , 4° C . , for 15 min to 15 polymer to fully swell . The microgels were centrifuged 
separate solids from the fluids . The supernatants were again , the supernatant removed , and the remaining polymer 
retained as rat gastric fluid and rat intestinal fluid , respec - flash - frozen in LN , followed by lyophilization . Fluorescent 
tively . Protein content of the fluids was measured using a microgels were incubated in PBS or trypsin at a concentra 
NanoDrop 1000 spectrophotometer ( Thermo Scientific , Wil - tion of 2 mg / ml for 90 minutes . Slides were prepared by 
imington , Del . ) . Fluids were stored at - 20° C . until use . 20 mounting 10 ul of particle solution on slides with ProLong® 
Degradation was evaluated by measuring relative turbid - gold antifade reagent . 
ity of the samples over time , as reported by Klinger and For cell uptake studies , coverslips ( 18 mm round , no . 1 . 5 
Landfester ( Klinger and Landfester , 2012 ) . Microgels were thickness ) were acid - washed overnight with 1 N HCl at 60° 
suspended in trypsin solutions of varying concentration , C . , rinsed with ethanol / water mixtures with successively 
PBS , SGF , SIF , or rat gastrointestinal fluids at various 25 increasing volume ratios of ethanol , and then the coverslips 
concentrations . 100 ul of each solution was added to a were placed in a 12 - well plate . RAW 274 . 6 cells were seeded 
96 - well plate in triplicate , and the absorbance was measured in the wells at a density of 115 , 000 cells / well . Microgels 
at 500 nm in 5 minute intervals over 90 minutes using a containing NBD - labeled nanogels , with or without fluores 
Bio - Tek SynergyTM HT multi - mode plate reader ( Winooski , cently labeled DY647 siRNA , were degraded at a concen 
Vt . ) . The temperature was controlled at 37° C . and the plate 30 tration of 2 . 5 mg / ml in 0 . 6 mg / ml trypsin for 60 minutes then 
underwent shaking for 3 seconds before each measurement . incubated at 70° C . for 5 minutes to deactivate trypsin . 24 
Activity of the trypsin following incubation with particles hours after plating the cells , the media was aspirated and 
and deactivation methods including addition of serum - con - replaced with 0 . 4 ml OptiMEM and 0 . 1 ml of degraded 
taining cell culture media and 5 minutes incubation at 70° C . microgel solution . Lipofectamine 2000 ( Life Technologies ) 
was evaluated using a trypsin activity assay adapted from 35 loaded with fluorescently labeled DY647 siRNA was used as 
the protocol by Yanes et al . ( Yanes et al . , 2007 ) . Briefly , a positive control for siRNA delivery . Cells were incubated 
degradation supernatant was combined with 1 mg / ml BAEE with the particles or Lipofectamine 2000 for 18 hours . 
in PBS at a 1 : 9 sample : BAEE ratio by volume . Immediately After the incubation period , the media was aspirated and 
after addition of the BASE , absorbance at 253 nm was the cells were washed 3x with cold Dulbecco ' s phosphate 
measured at the minimum interval ( typically 40 - 50 seconds ) 40 buffered saline ( DPBS , Sigma - Aldrich ) , fixed with cold IC 
for 5 minutes using a Bio - Tek SynergyTM HT multi - mode fixation buffer containing 4 % paraformaldehyde ( Life Tech 
plate reader ( Winooski , Vt . ) . nologies ) , and washed 3x wish cold HycloneTM Hank ' s 
Evaluation of siRNA Stability by Polyacrylamide Gel balanced salt solution ( HBSS , Fisher Scientific ) . In some 
Electrophoresis : cases , the cell membrane was stained with 1 ug / ml Alex 
For polyacrylamide gel electrophoresis , samples were 45 aFluor® 594 conjugated wheat germ agglutin ( Life Tech 
degraded in trypsin concentrations from 0 . 3 - 1 . 2 mg / ml for n ologies ) for 10 minutes then washed 2x with cold HBSS 
90 min then the trypsin was deactivated with DMEM or and once with cold , sterile DI water . ProLong® gold anti 
heat . Samples were also incubated in rat gastric fluid , rat fade reagent with or without DAPI stain ( Life Technologies ) 
intestinal fluid , PBS , or SGF to determine release and was used to mount the coverslips on acid - washed slides . 
stability of siRNA . Competitive polyanion assays were 50 Slides were stored at - 4° C . until imaging . 
completed using solutions of heparin sodium salt from Slides were imaged with Zeiss LSM 710 confocal micro 
porcine intestinal mucosa ( Sigma - Aldrich ) to competitively scope with 40x - and 63x - oil objectives . Sequential scanning 
complex with the polycationic nanogels and promote siRNA was used to eliminate emission bleed - though between chan 
dissociation from the nanogels . Ribonuclease A from bovine nels . The pinhole was set to 1 AU in the green channel . The 
pancreas ( RNAse A ) ( Sigma - Aldrich ) was used as a positive 55 gain and offset for each channel were set using single stain 
degradation control ; siRNA was incubated in a 0 . 05 mg / ml controls , and were kept constant for the full series of images 
RNAse A solution for 90 minutes at 37° C . Samples were to allow image comparisons . Images were collected in 8 bit 
diluted 1 : 1 by volume with Novex® TBE - urea sample format with an average = 4 to reduce noise , and all images 
loading buffer ( 2x ) ( Life Technologies ) , denatured at 70° C . underwent identical postprocessing ( y = 0 . 7 for red , blue , and 
for 3 min , and loaded into a Novex® TBE - urea denaturing 60 green channels , y = 0 . 1 . 3 for bright - field ) . 
polyacrylamide gel with 15 % crosslinking ( Life Technolo - ImageStream Flow Cytometry : 
gies ) . The gel was run at constant 180V for 70 min in 1x Microgels containing NBD - labeled nanogels and were 
Novex® TBE running buffer ( Life Technologies ) . Following incubated in PBS ( pH 7 . 4 ) or 0 . 6 mg / ml trypsin solution at 
the run , the gel was stained with SYBR green II ( Sigma - 1 . 5 mg / ml for 60 min then the trypsin was deactivated by 
Aldrich ) diluted 1 : 10 , 000 by volume in 1xTBE running 65 incubation at 70° C . for 5 minutes . Analysis of nanogel 
buffer for 30 minutes with shaking , the gel was rinsed with distribution and microgel degradation was conducted using 
DI water for 5 minutes with shaking , and then the gel was Amnis ImageStream ( Seattle , Wash . ) imaging flow cytom 
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eter . Nanogels were excited with a 488 laser and detected in Upon addition of the peptide , the mixture was immedi 
channel 2 ( 505 - 560 nm ) and bright field images were ately turbid and precipitation of brown , crosslinked hydrogel 
collected in channel 4 ( 595 - 660 nm ) . At least 10 , 000 events was evident . After the reaction was complete , the hydrogel 
were collected for analysis . Out - of - focus particles and was washed by repeated centrifugation and resuspension in 
debris were excluded from the analysis by gating the Gra - 5 DI water to remove impurities . The supernatant was retained 
dient RMS feature in IDEAS® software ; typically , events from each wash to determine the incorporation efficiency of 
with Gradient RMS value < 50 were considered out of focus . the nanogels . Following the washes , the hydrogel was frozen 
Fluorescence intensity in the green channel was gated to in LN , and lyophilized . The dry product appeared as fluffy brown chunks , and was easily crushed into a powder con intensity values > 3000 . 
Cell Transfection : 10 sisting of particles < 30 um in size . 
RAW 264 . 7 cells were seeded at 10 , 000 cells / well in Incorporation of Polycationic Nanogels 
96 - well cell culture plates for transfection studies . The RAW The fluorescence of the nanogels in the wash supernatant 
264 . 7 cells were allowed to incubate approximately 48 hours was measured using a Bio - Tek SynergyTM HT multi - mode 
and the Caco - 2 cells approximately 24 hours , until they y plate reader and compared to the fluorescence values of 
known concentrations of nanogels . It was determined that reached a confluence of about 50 % . 30 - 40 % of the nanogels were incorporated into the hydrogel , After the appropriate cell growth period , microgels were bringing the final weight ratio to 3 - 4 % with respect to the loaded with siRNA for transfection studies using the same 
conditions described in Section 7 . 2 . 4 . Microgels were polymer weight . 
loaded with AllStars Mm / Rn Cell Death Control siRNA , Incorporation of the polycationic nanogels was visualized 
AllStars Hs Cell Death Control siRNA . or Negative Control 20 using confocal laser scanning microscopy . The hydrogel 
siRNA at a loading concentration of 400 nM . Microgels particles were labeled with a TAMRA fluorophore that was 
were degraded at a concentration of 3 . 5 or 2 mg /ml in 0 . 3 reactive to carboxylic acid functional groups on the P ( MAA 
mg / ml trypsin in PBS at 37° C . for 90 minutes . Nanopar CO - NVP ) . After purification , the particles were lyophilized 
ticles were complexed with siRNA ( AllStars Mm / Rn Cell and a known weight was resuspended in PBS ( pH 7 . 4 ) . 
Death Control siRNA . AllStars Hs Cell Death Control 25 Slides were prepared by dropping the particle solution onto 
a slide and fixing the coverslips with ProLong® gold anti siRNA , or Negative Control siRNA ) in 1xPBS pH 5 . 5 at 
0 . 125 mg / mL nanoparticles and 400 nM siRNA for ~ 15 prior fade reagent . Imaging of the particles confirmed the pres 
to addition to cells . siRNA ( 400 nM ) was incubated with 2 ence of the nanogels ( green ) within the P ( MAA - CO - NVP ) particles ( red ) , as seen in FIGS . 12A - D . The porous structure ul Lipofectamine 2000 ( positive control ) in 78 ul OptiMEM 
for ~ 15 minutes prior to addition to cells . 30 of the hydrogels was also discernible in the bright field 
The microgels were added to cells at a final concentration image , in FIG . 12D . A Z - stack image , FIG . 13 , was obtained 
of 0 . 7 and 0 . 4 mg / mL in OptiMEM , nanoparticles were to verify the distribution of nanogels throughout the particle . 
added to cells at a final concentration of 0 . 025 mg / ml in Though the nanogels were throughout the particle , they did 
OptiMEM , and the Lipofectamine 2000 loading solution tend to be present in clusters or pockets , which is consistent 
was added to cells at a 1 : 5 dilution in OptiMEM Cells were 35 with the method of crosslinking . 
incubated with particles for 48 hours , at which point the Degradation of Microgels with Nanogels 
media was removed by aspiration and replaces with Cell Degradation studies with SIF , SGF , trypsin , and PBS were 
Titer 96® Aqueous One Solution Cell Proliferation MTS completed to verify that incorporation of the nanogels did 
Assay ( Promega ) . Cells were incubated with MTS solution not affect degradation kinetics . As observed in hydrogels 
for 90 minutes , and the absorbance at 490 and 690 nm was 4 40 without nanogels , the turbidity of the particle solutions 
measured with a Bio - Tek SynergyTM HT multi - mode plate could be used as a measure of degradation over time . FIG . 
reader ( Winooski , Vt . ) . The viability results for the AllStars 14 shows the decrease in turbidity over time of 1 . 5 - 6 mg / ml 
Death and the Negative Control siRNA were compared by microgels in 0 . 6 or 1 . 2 mg / ml trypsin . All concentrations 
Student ' s t test ( two - tailed , unequal variance ) to check for plateaued at the lowest turbidity value within 90 minutes , 
statistically significant silencing . The silencing efficiency 45 which was approximately the same as microgels containing no nanogels . Therefore , it does not seem as if the nanogels was evaluated using the absorbance of cells with death 
siRNA and cells with negative control siRNA as shown in significantly affect the degradation kinetics . However , as the 
Eq . 7 . 1 : relative turbidity plateaued at values of 18 % and higher , it is possible that the nanogels prevent complete degradation of 
50 the microgels . This may be attributed to the reaction of some 
of the amine groups present in the nanogels during the A Death silencing efficiency = 100x { 1 - EDC - NHS crosslinking reaction , effectively incorporating 
the nanogels as nondegradable crosslinks within the gel . 
While this is an undesirable side reaction that reduces the 
Results 55 number of nanogels able to be released from the microgels , 
P ( MAA - CO - NVP ) was synthesized and crosslinked with it is thought to be limited by the protection of the amine 
peptide as described in Example 1 , the only difference being groups via NBD - C1 and is not prevalent enough to affect the 
the addition of polycationic nanogels prior to the addition of ability of the microgels to degrade . 
the peptide . The polycationic nanogels were added at 10 wt It was further noted that the initial change in turbidity over 
% with respect to polymer weight and appeared brown in 60 the first 20 minutes of exposure to trypsin was linear , as 
color due to the conjugated fluorophore NBD - Cl . Prior to shown in FIG . 15A ( 1 . 2 mg / ml trypsin ) and FIG . 15B ( 0 . 6 
use in the microgels , NBD - C1 was reacted in excess to mg /ml trypsin ) . The corresponding microgel to trypsin ratio 
primary amines present in the nanogels to serve a dual versus initial rate of turbidity decrease values were then 
purpose ; first , to impart fluorescent detection of the nano - plotted to determine the relationship . The fit was nearly 
gels , and second , to protect the primary amines from react - 65 linear , as shown in FIG . 16 ( R = 0 . 98 ) , and may be used to 
ing during the EDC - NHS reaction with the peptide cross approximate degradation time of a known microgel to 
link . trypsin weight ratio . 
7 . 1 
A Negative 
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Additionally , trypsin activity assays with BAEE were the samples at exactly at time zero , some degradation had 
performed to ensure the quenching of trypsin activity prior already occurred in the trypsin samples at the nominal time 
to exposure to cells . Microgels were incubated with 1 . 2 zero . Consequently there was a slight misrepresentation of 
mg / ml or 0 . 6 mg / ml trypsin in pH 7 . 4 PBS for 90 minutes the particle size and fluorescent intensity in the trypsin 
at 37° C . , and then subjected to deactivation by incubation 5 samples at the nominal time zero . 
at 70° C . for 5 minutes or addition of 2x volume DMEM However , the size and fluorescence visualization of the 
containing serum . FIG . 17A shows the complete deactiva - microgels after 120 minutes of incubation was very indica 
tion of 1 . 2 mg / ml trypsin by both heat and DMEM compared tive of the degradation over a longer period of time . FIGS . 
unadulterated trypsin solutions , and FIG . 17B shows the 22A - C shows representative images of the microgels in each 
same for 0 . 6 mg / ml trypsin solutions . Therefore , it was 10 condition and FIGS . 23A - C shows histogram plots of the 
concluded that either was a satisfactory method of deacti corresponding microgel size distributions . It is apparent 
vating trypsin at concentrations at and below 1 . 2 mg / ml . from the images that again the size , morphology , and fluo 
As further confirmation of nanogel incorporation as well rescence intensity of microgels exposed to SIF and trypsin 
as visualization of degradation on the micro - scale , microgels had discernible differences from that of microgels incubated 
in various solutions were imaged with ImageStream flow 15 in SGF , a non - degrading buffer . The degraded particles were 
cytometry . This equipment enabled the analysis of entire small in size and entirely fluorescent compared to their 
populations of microgels using parameters such as fluores - larger undegraded counterparts with diffuse clusters of fluo 
cence intensity in a particular channel or particle size as rescence . The histogram plots confirm quantitatively that the 
detected by bright field imaging . It allowed real - time imag - size range decreased upon exposure to degrading buffers , 
ing and quantification of the change in particle size distri - 20 and the median sizes were 65 um ? in SGF to 25 and 26 um ? 
bution during degradation . in SIF and trypsin , respectively . Therefore , after 120 minutes 
Representative images obtained via ImageStream analysis of incubation in the buffers , the median size of the microgels 
of microgels incubated for 90 minutes in 1 . 2 mg / ml trypsin , in SGF did not decrease , as expected , while the median sizes 
0 . 6 mg / ml trypsin , or pH 7 . 4 PBS are shown in FIG . 18A , of microgels exposed to SIF and trypsin did decrease due to 
FIG . 18B , and FIG . 18C , respectively . Analysis of the 25 degradation . 
microgel populations confirmed that at least 70 % of the FIG . 24 shows the median microgel size ( um ) at each 
events detected had fluorescent intensities above a minimum time point in each of the three buffers . It can be seen that 
threshold . Further , the events were gated to remove out - of - median size of the particles incubated in SGF fluctuated over 
focus particles and debris from further analysis . The images time , but did not follow a decreasing trend . The median size 
revealed distinct differences in the size and morphology of 30 of particles incubated in SIF , on the other hand , gradually 
the microgels following incubation in the trypsin or PBS decreased over the 120 minute incubation period , as would 
solutions ; microgels exposed to trypsin are smaller in size be expected of microgels slowly degraded in the presence of 
and less porous in appearance than microgels exposed to a physiologically relevant concentration of trypsin . Micro 
only PBS . Additionally , the fluorescence intensity is very gels exposed to 1 . 2 mg / ml trypsin , however , decreased in 
strong and dense in the trypsin samples , whereas it is more 35 median size due to degradation by the time of the first 
diffuse throughout the PBS samples . This could be an measurement and did not degrade further over the 120 
indication of formation of strongly fluorescent and highly minute period . 
compact complexes between nanogels and degraded hydro Cytotoxicity of Degraded Microgels with Nanogels 
gel due to electrostatic binding , rather than diffusion of As the degradation behavior of the microgels containing 
nanogels from the degradation hydrogel as desired . 40 nanogels was consistent with a relevant timescale in simu 
The size distribution of the events was also plotted in lated intestinal conditions , the next step was to ensure the 
histogram form to better quantify the change in size as a cytocompatibility of the degraded and undegraded micro 
function of degradation . FIGS . 19A - C compares the histo - gels in trypsin solutions of varying concentration . These 
gram plots of microgels incubated in ( FIG . 19A ) 1 . 2 mg / ml studies were critical , as both polycationic polymers such as 
trypsin , ( FIG . 19B ) 0 . 6 mg / ml trypsin , and ( FIG . 19C ) PBS . 45 the nanogels ( Fischer et al . , 2003 ) and active trypsin ( Kaplan 
It was observed that compared to the PBS control the size and Bona , 1974 ; Unanue , 1984 ) , can have a detrimental 
range of microgels was greatly reduced from a maximum of effect on cell health and metabolism . Caco - 2 human adeno 
2800 um? to 600 um? upon incubation in trypsin , as would carcinoma cells , often used to model the intestinal epithe 
be expected due to enzymatic degradation . Also convincing lium , and RAW 264 . 7 murine macrophage , used to model 
was the shift in median particle area from 163 um ' in PBS 50 target cells for nanogel uptake , were used in these studies . 
to 39 um ? in trypsin . Two cytotoxicity assays were used ; the MTS cell prolifera 
Similar results were obtained using ImageStream to visu - tion assay was indicative of any changes to cell metabolism 
alize large populations of microgels incubated in SGF , SIF , upon exposure to microgels , and the LDH membrane integ 
or 1 . 2 mg / ml trypsin solution . Samples were run after 0 , 15 , rity assay was indicative of the viability of cells after 
30 , 60 , and 120 minutes of incubation in each of the 55 exposure . 
conditions . As before , events were gated by fluorescence Microgels were incubated in 1 . 25 or 0 . 625 mg / ml trypsin 
intensity as well as gradient RMS , a metric used to gate for solution for at least 4 hours to ensure degradation of the 
images in the focal plane . FIGS . 20A - C compares represen microgels ; PBS buffer was used as a control . Trypsin was 
tative images of microgels in each of the solutions at time deactivated by the addition of excess cell media prior to the 
zero , and FIGS . 21A - C compares the histogram plots of the 60 addition to Caco - 2 cells . Cells were incubated with degraded 
size distribution of events in each solution at time zero . The microgel solutions for 18 hours to assess cytotoxic effect . 
size distribution of microgels in SGF and SIF was much FIG . 25A and FIG . 25B show Caco - 2 cell proliferation and 
broader than that of microgels in trypsin , and again the viability , respectively , as a function of microgel and trypsin 
fluorescence was more diffuse in particles incubated in SGF concentration relative to cells incubated in normal media 
and SIF than in trypsin . The median microgel sizes were 54 , 65 without microgels . The cell proliferation was affected by the 
79 , and 23 um ? in SGF , SIF , and trypsin , respectively . degraded microgels in a concentration - dependent manner ; 
Unfortunately , since it was not logistically possible to run the highest concentration of 2 mg / ml induced an unaccept 
39 
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able amount of change in cell metabolism as measured by ing in less degradation being less detrimental to cell viabil 
the MTS assay . However , all concentrations maintained very ity . In fact , undegraded microgels in PBS were significantly 
high cell viability after 18 hours of incubation . Thus , high less toxic at 70 % viability than microgels incubated in the 
concentrations of degraded microgels may affect the lowest trypsin concentration , at 40 % viability . This strongly 
metabolism of Caco - 2 cells , but the do not kill the cells . 5 suggests that the degradation products or release of nanogels 
A comprehensive study evaluating effect of trypsin con from degraded microgels has a detrimental effect on cell 
centration , culture medium , and trypsin concentration dur membrane viability at this concentration . ing degradation was performed in the RAW 264 . 7 cells . At the reduced concentration of 0 . 4 mg / ml in OptiMEM Microgels at a concentration of 2 mg / ml were degraded in shown in FIG . 27C , however , cell viability is quite high at 0 . 15 , 0 . 2 , 0 . 25 , and 0 . 3 mg / ml trypsin for 90 minutes at 37° 10 > 80 % for all conditions tested . In subsequent cell transfec C . , and then the trypsin was deactivated by incubation at 70° tion studies , these conditions were used to induce minimal C . for 5 minutes . The microgels were then added to the cells 
at a final concentration of 1 mg / ml or 0 . 4 mg / ml in toxic effect as a result of microgels or degradation condi tions . OptiMEM or 1 mg / ml in DMEM . Two different culture 
media were tested as the OptiMEM is a reduced - serum 15 15 ? siRNA Loading 
medium , and the presence of serum is thought to negatively Loading studies were conducted with the Silencer® 
impact cellular uptake and transfection by nanoparticles . Select Negative Control No . 1 scrambled sequence siRNA at 
Therefore , it was hypothesized that increased uptake of 1000 nM or 400 nM to evaluate the ability of the microgels 
nanoparticles with inherently cytotoxic cationic functional to load siRNA . Microgels were incubated with the siRNA at 
groups may be more disruptive to the cell metabolism or cell 20 a particle concentration of 12 mg / ml in pH 5 . 5 PBS for up 
membrane . to 4 hours at room temperature with agitation . The loading 
FIGS . 26A - C shows the results of the MTS cell prolif pH was selected as both the microgels and nanogels are 
eration assay following incubation of the RAW 264 . 7 cells partially charged at this condition , facilitating swelling of 
with the degraded microgels for 18 hours . Absorbance at 490 the hydrogel networks to allow increased diffusion of siRNA 
nm is relative to that of cells exposed only to culture medium 25 to complex with the positively charged nanogels . Following 
for the 18 hour incubation period . In all three exposure incubation , the microgel / siRNA solutions were centrifuged 
conditions , undegraded microgels in PBS were slightly less to separate loaded microgels from siRNA remaining in 
disruptive to cell metabolism than degraded microgels , solution . Afterwards , the siRNA content in the supernatant 
suggesting that degradation of the microgel matrix does was measured with the Quant - iTTM RiboGreen RNA 
cause increased cellular exposure to the potentially cytotoxic 30 Assay Kit . 
polycationic nanogels within . Loading efficiencies were calculated as follows , where co 
FIG . 26A shows that the 1 mg /ml microgel concentration is the initial molar siRNA concentration , cris the final molar 
in OptiMEM did have an effect of cellular metabolism , as siRNA concentration , and c , is the mass concentration of 
the relative absorbance was reduced below 50 % at all polymer in solution : 
trypsin concentrations . Also important to note is that cells 35 
exposed to the deactivated trypsin without microgels also 
experienced a reduction in relative absorbance , indicating Loading Efficiency = O F ( 7 . 2 ) * 100 
the negative effect of high trypsin concentrations on cell 
metabolism . 
FIG . 26B indicates that the same microgel concentration 40 Weight Loading Efficiency = ( 7 . 3 ) * 100 
in serum - containing DMEM resulted in less effect on cell 
metabolism due to the degraded microgels , as the relative 
absorbance of trypsin with and without microgels was Representative weight and loading efficiencies of the 
approximately the same . This could be due to the serum scrambled siRNA are shown in FIG . 28 . This scrambled 
content causing nonspecific protein binding to the nanogels , 45 siRNA sequence achieved weight efficiencies of 0 . 06 and 
resulting in a reduction in both cytotoxicity and cellular 0 . 02 nmol siRNA / mg polymer and loading efficiencies of 
uptake . It is important to note , though , that this concentra - 75 % and 59 % in 1000 nM and 400 nM siRNA loading 
tion of microgels did result in a 30 % reduction in absorbance concentrations , respectively . The weight and loading effi 
relative to the control cells incubated in DMEM only . ciencies were highest in the loading solution with the greater 
Therefore , this microgel concentration still significantly 50 siRNA concentration , as would be expected due to the 
affects cell metabolism . greater concentration gradient acting as a diffusional driving 
Finally , FIG . 26C shows the results of the MTS assay of force . In general for a variety of siRNAs tested , weight 
RAW 264 . 7 cells incubated with 0 . 4 mg / ml degraded micro efficiencies ranged from 0 . 02 - 0 . 11 nmol siRNA / mg poly 
gels in OptiMEM culture medium . As expected , the lower mer , and loading efficiencies ranged from 59 - 90 % . The 
microgel concentration resulted in less disruption of cell 55 variation in loading efficiency was attributed to batch - to 
metabolism relative to cells exposed only to OptiMEM , with batch variability in the microgels as well as differences in 
a decrease in relative absorbance of only - 25 % across all siRNA sequences . Incubation time for loading did not 
trypsin concentrations . There was also little difference in greatly affect efficiencies , and consequently the loading 
relative absorbance between cells incubation deactivated period was reduced to 1 . 5 hours to limit degradation of 
trypsin alone or deactivated trypsin with degraded micro - 60 siRNA by hydrolysis . 
gels . The loading efficiencies were consistently lower than 
The results from the LDH assay , shown in FIGS . 27A - C , those achieved with nanogels alone ( Forbes and Peppas , 
mirror the results from the MTS assay , with the only notable 2014 ) , but this was to be expected due to the increased 
exception being a much more pronounced effect of 1 mg / ml complexity of diffusion through the microgel matrix as well 
degraded microgels in DMEM on membrane integrity , 65 as the possibility of unfavorable electrostatic repulsion 
shown in FIG . 27B . Interestingly , this negative effect was a between the polyanionic P ( MAA - CO - NVP ) and negatively 
function of microgel : trypsin ratio , with ratios likely result charged siRNA . Overall , the results indicate that these 
?? 
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concerns are not prohibitive to loading siRNA into the As a control , siRNA was incubated in 0 . 05 , 0 . 1 , and 0 . 5 
microgels as significant loading of the siRNA was achieved . mg / ml Ribonuclease A to fully degrade the siRNA . 
Microgel Degradation and siRNA Stability FIG . 30A shows the PAGE results . Intact siRNA bands 
As siRNA is quite susceptible to degradation by proteases were clearly shown in lanes 1 ( without heparin ) and 5 ( with 
( Fattal and Bochot , 2008 ) , there was concern that the 5 heparin ) , though some bands of degraded siRNA were also 
stability and integrity of the siRNA could be compromised present . Faint bands of intact siRNA were present in the 
during the trypsin - induced degradation of the microgels . nanogel samples ( lanes 2 and 6 ) as well as in one of the 
Therefore , the stability of the siRNA following incubation in degraded microgel samples ( lanes 4 and 8 ) . Again , it seemed 
various conditions was evaluated by polyacrylamide gel as if heparin had no effect on the amount of free siRNA . It 
electrophoresis ( PAGE ) , as has been reported previously in " was unexpected that only one of the microgel samples 
the literature ( Hickerson et al . , 2008 ) . PAGE separates contained intact siRNA , it is possible that the sample in 
molecules by electrophoretic mobility , which is a function of lanes 3 and 7 was contaminated with an RNase . The bands 
the size , conformation and charge of the molecule . Thus , it of siRNA fully degraded by RNase can be seen in lane 9 ; the 
is widely used to determine the stability of various biologi - 16 higher concentrations of RNase degraded the siRNA to such 
cal molecules including proteins , RNA , and DNA . an extent that it ran off the gel and was no longer detectable . 
In the case of denaturing PAGE , as was utilized in the To verify that the degradation observed in all samples was 
studies herein , the higher order structure of the siRNA was not due to the incubation temperature or pH at which the 
denatured by exposure to urea , limiting the dependence of siRNA was incubated , siRNA alone was incubated on ice , at 
electrophoretic mobility to size and charge alone . In this 20 room temperature followed by 90° C . for 5 minutes , pH 5 . 5 
way , the degradation of siRNA in various conditions was PBS at 37° C . , pH 8 . 5 PBS at 37° C . , with microgels at 
examined . Microgels with nanogels loaded with siRNA , loading conditions , and in 1 . 2 or 0 . 6 mg / ml trypsin with and 
nanogels complexed with siRNA , and siRNA alone were without particles at 37° C . As shown in FIG . 30B , only the 
incubated in 0 . 3 mg / ml trypsin in PBS , rat intestinal fluid , rat siRNA exposed to trypsin , with or without microgels , expe 
gastric fluid , PBS , or SGF for 90 minutes at 37° C . followed 25 rienced degradation . This confirms that the high trypsin 
by 5 minutes incubation at 70° C . to deactivate trypsin . activity was the culprit behind the degraded siRNA and not 
Microgels were incubated at a concentration of 5 mg / ml , hydrolysis at elevated temperature . 
nanogels at a concentration of 0 . 4 mg / ml , and siRNA at a The concentrations of trypsin used in these studies are 
concentration of 400 nM . FIG . 29A shows the image of the much higher than physiologically relevant trypsin levels . As 
gel ; it was noted that the samples incubated with trypsin 30 demonstrated in rat intestinal fluid , it is anticipated that the 
showed signs of significant siRNA degradation , evidenced ability of these microgel systems to deliver intact siRNA in 
by the smaller molecular weight bands in lanes 1 , 6 , and 11 . physiological or in vivo conditions may be significantly 
Without wishing to be bound by any theory , it was positive greater than these studies project . 
that at least some of the siRNA remained stable in rat Confocal Microscopy to Verify Internalization 
intestinal fluid and PBS ( lanes 2 , 7 , 12 and 4 , 9 , 14 , 35 Confocal laser scanning laser microscopy was used to 
respectively ) . As expected , rat gastric and SGF conditions verify cellular internalization of nanogels from degraded 
resulted in noticeable siRNA degradation ( lanes 3 , 8 , 13 and microgels . Microgels containing fluorescently tagged nano 
5 , 10 , 15 , respectively ) . siRNA release from the degraded gels were incubated in 0 . 6 mg / ml trypsin for 90 minutes to 
microgels and nanogels was observed , as evidenced by the degrade the microgel matrix and allow release of the nano 
bands corresponding to the stable siRNA band in lane 14 . 40 gels . Following degradation , the samples were incubated at 
The same siRNA - loaded samples incubated in the various 70° C . for 5 minutes to deactivate the trypsin and the 
conditions were then incubated in 0 . 5 mg / ml heparin in degraded microgels were added to cells at a final concen 
OptiMEM to better evaluate release of siRNA in the various tration of 0 . 5 mg / ml in OptiMEM . The cells were incubated 
conditions . Heparin was used as a competitive polyanion to for 18 hours with the degraded particles then fixed , stained 
induce dissociation of the siRNA from the polycationic 45 with fluorescently labeled wheat germ agglutinin , a cell 
nanogels , as other researchers have reported ( Moret et al . , membrane marker , then extensively washed and mounted 
2001 ; Zelphati et al . , 1996 ) . FIG . 29B shows the image of onto slides with ProLong® gold antifade reagent containing 
the gel of the samples after incubation with heparin . Again , DAPI nuclear stain . Nanogels alone were used for compari 
it was observed that free , undegraded siRNA was present in son , as the cellular internalization of the nanogels has been 
all samples with the exception of the samples incubated at 50 previously documented ( Forbes and Peppas , 2014 ) . All 
high trypsin concentration . The presence of heparin did not images were representative of the entire cell population ; in 
seem to increase dissociation of the siRNA . Of course , it is each condition tested , the cells were at approximately 60 % 
impossible to say conclusively whether or not the free confluence and appeared to be in good health as determined 
siRNA increased upon incubation with heparin without by the bright field images . 
extracting and quantifying siRNA in the gel , but it was 55 FIGS . 31A - B shows the fluorescent and bright field 
determined that the effort required to quantify the siRNA images of RAW 264 . 7 cells incubated with nanogels ( FIG . 
was not justified in this experiment . The presence of free , 31A ) and degraded microgels containing nanogels ( FIG . 
undegraded siRNA following incubation in physiologically 31B ) . In both cases , comparison of the artificially - colored 
relevant proteolytic conditions was confirmed , and this green in the third panel with the bright field images in the 
proof - of - concept was sufficient for these studies . 60 fifth panel as well as the fluorescent overlay in the fourth 
Looking for closely at the effect of trypsin on siRNA panel indicated the presence of nanogels in proximity to the 
stability , siRNA , siRNA complexed with nanogels , and nuclei of cells , suggesting internalization . Interesting to note 
microgels with nanogels loaded with siRNA were degraded is the high prevalence of micron - size particles with green 
in 0 . 6 mg / ml trypsin for 1 hour at 37° C . , and then the trypsin fluorescence both near and around the cells in the degraded 
was deactivated by incubation at 70° C . for 5 minutes . One 65 microgel samples ; this lends credibility to the working 
set was added to PBS an identical set was added to a 0 . 5 theory that upon degradation the nanogels do not completely 
mg / ml heparin solution to promote dissociation of siRNA . release from the microgel matrix . Rather , they may be 
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electrostatically bound with degraded microgel products in is still much less than what has been previously reported of 
a highly fluorescent complex that is microns in size . these particles ( Forbes and Peppas , 2014 ) , so it is possible 
To verify internalization of nanogels , Z - stack images that the experimental conditions are not conducive to high 
through the cells were taken . An orthogonal view of the transfection and silencing . It is much more likely , however , 
Z - stacks , shown in FIGS . 32A - B , confirmed the presence of 5 that the electrostatic interactions between P ( MAA - CO - NVP ) , 
the nanogels within the artificially - colored red cell mem the nanogels , and the siRNA are complicating transfection 
branes . Within the orthogonal view , the main panel displays and silencing . Additionally , as the MTS assay is a measure 
the x - y plane , the bottom panel displays the x - z plane , and of cell metabolism rather than cell death , it may not be the 
the right panel displays the z - y plane . In both the cells with ideal assay to evaluate silencing efficiency . It was used in 
these studies to allow for direct comparison to the previous nanogels , FIG . 32A , and the cells with degraded microgels 10 work by Forbes and Peppas , 2014 . and nanogels , FIG . 32B , the nanogels were localized within However , a positive aspect of the transfection studies was the cells membranes , which was likely indicative of endo that the viability of the cells exposed only to the various somal compartmentalization . In the case of the degraded hydrogel particles ( no siRNA ) was consistently at or greater 
microgels with nanogels , at least some of the potentially than 60 % . Toxicity of transfection agents is a continual 
electrostatically - bound nanogel complexes were still able to 15 challenge in delivering siRNA , and fortunately neither the 
be internalized by cells . Therefore , the complexation does nanogels nor the degradable microgels containing nanogels 
not entirely prohibit internalization , but may affect efficacy induced very high levels of toxicity during transfection . Also 
and siRNA delivery . encouraging was the repeatability of these results in separate 
With the goal of getting a better idea of the electrostatic studies ; though well - to - well variability was high for a few 
interactions between the microgels , nanogels , and siRNA , 20 samples , the magnitude of average silencing efficiency and 
all three of which are charged species , microgels and nano - viability was consistent from study to study as well as across 
gels loaded with DY 647 - siRNA were also degraded and cell lines , making the results more credible . 
incubated with RAW 264 . 7 cells in the same manner . FIGS . As shown by the data above , nanogels were encapsulated 
33A - C shows images of cells incubated with FIG . 33A ) in enzymatically - degradable P ( MAA - CO - NVP ) microgels 
degraded microgels containing nanogels and siRNA : FIG . 25 via a facile crosslinking reaction . Nanogel incorporation and 
33B ) nanogels complexed with siRNA ; and FIG . 33C ) distribution was confirmed by fluorescent spectroscopy and 
TAMRA - labeled microgels with nanogels and siRNA . confocal microscopy . Enzyme - specific degradation of the 
Again , in all three cases the fluorescence of the nanogels in microgels was evaluated by decrease in relative turbidity over time as well as ImageStream flow cytometry ; the relation to the bright field image suggests that cellular degradation timescale was relevant to intestinal residence uptake of the nanogels may be occurring . Additionally , the 30 time and the degradation products induced minimal cyto fluorescence of the siRNA is in good spatial agreement with toxic effects at low concentrations . the nanogel fluorescence , indicating complexation between siRNA was efficiently loaded into the microgel systems 
the two species . As before , the relatively large clusters of due to equilibrium partitioning and charge interactions . The 
degraded microgel and nanogels are visible around the cells siRNA did experience reduced stability following incuba 
in the bright field images of FIG . 33A and FIG . 33C , and 35 tion in the microgel degradation conditions at high trypsin 
there is associated fluorescence of each of the charged concentrations . Despite the attack by trypsin on the siRNA , 
molecules corresponds to these clusters . These data support a detectable amount was released from the microgel system 
the idea that complexation is occurring between microgels , and escaped degradation , especially in the physiologically 
nanogels , and siRNA . relevant buffers . Thus , this microgel system may be used for 
Transfection of Murine Macrophage and Human Adeno - 40 in vivo applications . 
carcinoma Cells Cellular uptake of nanogels released from degraded 
Transfection conditions were determined by the best microgels was confirmed in RAW 264 . 7 cells by confocal 
cytotoxicity , degradation , and siRNA stability results . RAW microscopy . Both ImageStream analysis and confocal 
264 . 7 murine macrophage and Caco - 2 human adenocarci - microscopy suggest that electrostatic complexation is occur 
noma cells were incubated with siRNA and degraded micro - 45 ring between the negatively charged degraded P ( MAA - co 
gels ( 0 . 4 and 0 . 7 mg / ml ) , undegraded microgels ( 0 . 7 NVP ) and positively charged nanogels , but some of the 
mg / ml ) , nanogels ( 0 . 025 mg / ml ), commercially available complexes , free nanogels , or both are internalized by the 
transfection agent Lipofectamine 2000 , or naked siRNA . cells . The transfection efficiencies are consistent across both 
Both cell lines were treated identically , with the exception of RAW 264 . 7 and Caco - 2 cell lines and may be increased by 
mouse and human variant AllStars Death siRNA . Silencing 50 optimization of the delivery system and transfection condi 
was measured by an MTS assay of cell proliferation relative tions . 
to that of scrambled siRNA controls . Experiments were run The performance of this system may be evaluated in vivo 
in quadruplicate and were repeated across two sets of each or in conditions more closely resembling in vivo to verify 
cell line . the biodegradability and silencing efficiency ; it is possible 
As shown in FIGS . 34A - B , similar gene silencing was 55 that a greater portion of the siRNA will remain stable at 
obtained in both the FIG . 34A ) RAW 264 . 7 and FIG . 34B ) physiological trypsin concentrations , and competing 
Caco - 2 cell lines . At all concentrations and conditions charged molecules in the intestinal environment may 
tested , the microgels were unable to achieve greater than decrease the electrostatic binding via competitive dissocia 
20 % silencing , and in some instances the variation between tion . 
experiments was quite large . In fact , in the RAW cells the 60 
silencing by the degraded microgels with nanogels was Example 3 
significantly less than the silencing by nanogels with siRNA 
( T - test , p < 0 . 05 ) . Silencing efficiency was of a similar mag siRNA Loaded Peptide Crosslinked Hydrogels 
nitude in the Caco - 2 cells , but none of the samples per 
formed significantly better than the others in this cell line . 65 Loading of siRNA into Nanogels 
Though the nanogels were able to achieve a significant NBD - labeled nanogels were loaded post - synthesis by 
silencing efficiency in the RAW 264 . 7 cells , the percentage with either Silencer® Select Negative Control No . 1 siRNA 
45 
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( Life Technologies ) or Silencer® Pre - designed siRNA tar were dosed at a concentration of 0 . 0125 mg nanogels / ml 
geting TNF - a ( Sense : CGUCGUAGCAAACCACCAA media . ( 3 ) Microgels ( 30 - 75 um ) containing nanogels 
( SEQ ID NO : 52 ) , Life Technologies , Gene ID : 21926 ) . loaded with either control or TNF - a siRNA were degraded 
Nanogels were incubated at a concentration of 0 . 125 mg / ml at a concentration of 2 . 5 mg / ml in 0 . 3 mg / ml trypsin in PBS 
at room temperature for 30 min in siRNA solutions ranging 5 at 37° C . for 90 minutes . Following degradation , solutions 
from 0 . 25 uM to 4 uM in nuclease - free PBS at pH ~ 5 . 5 . were diluted 10x in OptiMEM® , and cells were dosed at a 
Nuclease free 10xPBS was prepared by dissolving sodium concentration of 0 . 25 mg microgels / ml media . ( 4 ) Non 
chloride , potassium chloride , monobasic potassium phos degraded microgels ( 30 - 75 um ) loaded with TNF - a siRNA 
phate , and sodium phosphate dibasic heptahydrate in water , nanogels were also dosed to cells at a concentration of 0 . 25 
treating with 0 . 1 % v / v diethylpyrocarbonate ( DEPC ) over 0 . 1 % y / y diethylpyrocarbonate ( DEPC over 10 mg microgels / ml media . Cells were incubated exposed to these various transfec night , and then autoclaving to remove DEPC . Following tion agents for 24 hr . After 24 hr , media was changed to fresh loading , nanogels were collected by centrifugation at OptiMEM® containing 100 ng / ml lipopolysaccharide to 
15 , 000xg for 10 minutes . Loading of siRNA was evaluated induce an inflammatory response . After an additional 24 hr , by determining siRNA concentrations left in the supernatant supernatant 15 media was collected and assayed for TNF - a content using a after loading using a Quant - iTTM RiboGreen® RNA Assay Mouse TNF - a Quantikine ELISA Kit ( R & D Systems , Min Kit . Loading conditions of 0 . 125 mg / ml nanogels : 1 uM neapolis , Minn . ) . After media collection , cells were lysed 
siRNA were used for zeta potential measurements and using RIPA buffer and total DNA content was assessed using 
subsequent transfection studies . a Quant - iTTM PicoGreen DNA Assay Kit . Results are 
Synthesis of Peptide Crosslinked Hydrogels 20 reported as pg secreted TNF - a normalized to the total DNA 
Linear P ( MAA - CO - NVP ) was dissolved in a 1 : 1 ( v / v ) content of that group . 
water : ethanol solution at a concentration of 50 mg / ml . EDC Characterization and siRNA loading of P ( DEAEMA - CO 
was dissolved in ethanol at a concentration of 50 mg / ml and tBMA ) nanogels is shown in FIGS . 35A - D . 
NHS was dissolved in ethanol at a concentration of 16 siRNA Transfection and TNF - a Knockdown 
mg / ml . The EDC and NHS solutions were added to the 25 RAW 264 . 7 macrophages were exposed to five different 
polymer solution at a ratio of 6 : 3 : 1 polymer : EDC : NHS by conditions : ( 1 ) lipofectamine loaded with control or TNF - a 
weight . The solution was mixed by vortex briefly , and then siRNA , ( 2 ) nanogels loaded with control or TNF - a siRNA , 
allowed to react for - 3 min with shaking . Non - siRNA ( 3 ) degraded microgels with control or TNF - a siRNA 
loaded nanogels in a 10 mg / ml solution in ethanol were loaded nanogels , ( 4 ) no treatment , and ( 5 ) non - degraded 
added at 10 wt % relative to the P ( MAA - CO - NVP ) and the 30 he 30 microgels with TNF - a siRNA loaded nanogels . The amount 
solution was briefly mixed by vortex . The pH was raised to of secreted TNF - a protein from cells exposed to these conditions is displayed in FIG . 36 . approximately 8 by the addition of 1 N sodium hydroxide Lipofectamine , nanogels , and nanogels released from ( NaOH ) , and then a volume of 100 mg / ml peptide in ethanol degraded microgels were all capable of transfecting the 
solution was added to achieve a 2 : 1 weight ratio of polymer : 26 T : 35 macrophages , inducing knockdown of TNF - a secretion peptide . The mixture was allowed to react overnight with when TNF - a siRNA was delivered vs . a control siRNA shaking then purified by 3 wash cycles with water and ( p < 0 . 05 , Student ' s t - test ) . Additionally , the TNF - a secretion 
centrifugation at 10 , 000xg for 5 minutes . These microgels induced by these three conditions was significantly lower 
with non - siRNA loaded nanogels were used for initial than the macrophages receiving no treatment ( p < 0 . 05 , 
imaging and degradation studies . 40 ANOVA ) , further validating the potential for this strategy to 
In an analogous reaction scheme , nanogels were first be used to mitigate TNF - a production under inflammatory 
loaded with either control or TNF - a siRNA before encap - conditions . Cells exposed to non - degraded microgels with 
sulation in the P ( MAA - CO - NVP ) hydrogel . Nanogels at 10 encapsulated TNF - a siRNA loaded nanogels did not elicit 
mg / ml in PBS pH 5 . 5 were mixed with 80 uM siRNA and any knockdown of TNF - a production , indicating the micro 
allowed to electrostatically complex for 30 min . The reac - 45 gel platform must first be degraded before the nanogels can 
tion scheme was then followed as described above , except induce siRNA - mediated protein knockdown . 
PBS pH 5 . 5 was used as the solvent instead of water / ethanol Though the nanogels that were released from the 
and reaction pH was not adjusted . Reaction conditions at pH degraded microgels were able to achieve a significant silenc 
5 . 5 were chosen because under these conditions the siRNA ing efficiency in the RAW 264 . 7 cells , they were not as 
will remain electrostatically complexed with the nanogels . 50 effective as the non - encapsulated nanogels . It is possible that 
Following the washes , the polymer was frozen in liquid the electrostatic interactions between P ( MAA - CO - NVP ) , the 
nitrogen and lyophilized for at least 24 hours . After nanogels , and the siRNA are complicating transfection and 
lyophilization , the polymer was milled into a fine power by silencing . Additionally , the viability of the cells exposed 
crushing with mortar and pestle . The powder was sifted to only to the various hydrogel particles ( no siRNA ) was 
sizes of 30 - 75 um and less than 30 um by ultraprecision 55 consistently at or greater than 80 % for concentrations up to 
ASTM sieves ( Precision Eforming , Cortland , N . Y . ) . 4x higher than those used in transfection studies , leaving the 
Transfection and TNF - a Knockdown possibility of safely increasing the particle dosage . Toxicity 
RAW 264 . 7 macrophages were seeded at a density of of transfection agents is a continual challenge in delivering 
10 , 000 cells / well in a 96 - well plate and allowed to adhere siRNA , and fortunately neither the nanogels nor the degrad 
for 24 hr prior to the experiment . Media volumes were 60 able microgels containing nanogels induced very high levels 
maintained at 100 ul / well throughout the experiment . Four of toxicity during transfection . 
different transfection conditions were evaluated . ( 1 ) As a All of the methods disclosed and claimed herein can be 
positive control , Lipofectamine LTX was incubated with made and executed without undue experimentation in light 
either control or TNF - a siRNA at a concentration of 400 nM of the present disclosure . While the compositions and meth 
siRNA : 1 ul Lipofectamine and allowed to complex for ~ 10 65 ods of this invention have been described in terms of 
min prior to dosing cells at 0 . 1 ul Lipofectamine / ml media . preferred embodiments , it will be apparent to those of skill 
( 2 ) Nanogels were loaded with control or TNF - a siRNA in the art that variations may be applied to the methods and 
48 
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in the steps or in the sequence of steps of the method Forbes and Peppas , Polycationic nanoparticles for sirna 
described herein without departing from the concept , spirit delivery : Comparing arget atrp and uv - initiated formula 
and scope of the invention . More specifically , it will be tions . ACS Nano , 8 : p . 2908 - 2917 , 2014 . apparent that certain agents which are both chemically and 
physiologically related may be substituted for the agents 5 5 Forbes and Peppas , Polymeric nanocarriers for sirna deliv 
described herein while the same or similar results would be ery to murine macrophages . Macromol Biosci , 14 ( 8 ) : p . 
achieved . All such similar substitutes and modifications 1096 - 1105 , 2014 . 
apparent to those skilled in the art are deemed to be within Forbes et al . , Polycationic nanoparticles synthesized using 
the spirit , scope and concept of the invention as defined by by 10 arget atrp for drug delivery . Eur J Pharm Biopharm , 84 ( 3 ) : 
the appended claims . p . 472 - 478 , 2013 . 
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SEQUENCE LISTING 
< 160 > NUMBER OF SEQ ID NOS : 52 
< 210 > SEQ ID NO 1 
1 > LENGTH : 6 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 1 




< 210 > SEQ ID NO 2 
1 > LENGTH : 4 
< 212 > TYPE : PRT 
3 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 





< 400 > SEQUENCE : 2 




< 210 > SEQ ID NO 3 
< 211 > LENGTH : 4 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 3 
Gly Lys Gly Lys 
1 
< 210 > SEQ ID NO 4 
< 211 > LENGTH : 5 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 4 
Gly Arg Arg Gly Lys 
< 210 > SEQ ID NO 5 
< 211 > LENGTH : 5 
< 212 > TYPE : PRT 
3 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
? 
< 400 > SEQUENCE : 5 
Gly Arg Lys Gly Lys 
5 
< 210 > SEQ ID NO 6 




< 211 > LENGTH : 5 
< 212 > TYPE : PRT 
13 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 6 
Gly Lys Lys Gly Lys 
< 210 > SEQ ID NO 7 
< 211 > LENGTH : 6 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 7 
Gly Lys Arg Arg Gly Lys 
1 
A 
< 210 > SEQ ID NO 8 
< 211 > LENGTH : 6 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 




< 400 > SEQUENCE : 8 
Gly Lys Lys Arg Gly Lys 
< 210 > SEQ ID NO 9 
< 211 > LENGTH : 6 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 9 
Gly Lys Lys Lys Gly Lys 
< 210 > SEQ ID NO 10 
< 211 > LENGTH : 6 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 10 
Gly Arg Gly Arg Gly Lys 
1 
< 210 > SEQ ID NO 11 
< 211 > LENGTH : 6 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
N PEP
< 400 > SEQUENCE : 11 
Gly Lys Gly Lys Gly Lys 
1 
< 210 > SEQ ID NO 12 
< 211 > LENGTH : 7 
US 9 , 937 , 256 B2 
55 56 
- continued 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 12 
Gly Arg Arg Arg Arg Gly Lys 
< 210 > SEQ ID NO 13 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
13 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 13 
Gly Lys Arg Arg Arg Gly Lys 
< 210 > SEQ ID NO 14 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
13 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
A 
< 400 > SEQUENCE : 14 
Gly Arg Lys Arg Arg Gly Lys 
< 210 > SEQ ID NO 15 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
223 > OTHER INFORMATION : Synthetic peptide HN N MOM2 V 
< 400 > SEQUENCE : 15 
Gly Arg Arg Lys Arg Gly Lys 
< 210 > SEQ ID NO 16 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
3 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 




< 400 > SEQUENCE : 16 
Gly Arg Arg Arg Lys Gly Lys 
? 
< 210 > SEO ID NO 17 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 






< 400 > SEQUENCE : 17 
Gly Lys Lys Arg Arg Gly Lys 
Z 
< 210 > SEQ ID NO 18 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
US 9 , 937 , 256 B2 
57 58 
- continued 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 18 
Gly Arg Lys Lys Arg Gly Lys 
< 210 > SEQ ID NO 19 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 19 
Gly Arg Arg Lys Lys Gly Lys 
< 210 > SEQ ID NO 20 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 20 
Gly Arg Lys Arg Lys Gly Lys 
< 210 > SEQ ID NO 21 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
13 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
52 
< 400 > SEQUENCE : 21 
Gly Lys Arg Lys Arg Gly Lys 
< 210 > SEQ ID NO 22 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 22 
Gly Gly Arg Arg Arg Gly Lys 
< 210 > SEQ ID NO 23 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
223 > OTHER INFORMATION : Synthetic peptide ? 
< 400 > SEQUENCE : 23 
Gly Arg Gly Arg Arg Gly Lys 
< 210 > SEQ ID NO 24 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
US 9 , 937 , 256 B2 
- continued 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 24 
Gly Arg Arg Gly Arg Gly Lys 
? .
? 
< 210 > SEQ ID NO 25 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
? 
? 
< 400 > SEQUENCE : 25 
Gly Arg Arg Arg Gly Gly Lys 
< 210 > SEQ ID NO 26 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
13 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
? 
< 400 > SEQUENCE : 26 
Gly Gly Gly Arg Arg Gly Lys 
< 210 > SEQ ID NO 27 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
OWN 
< 400 > SEQUENCE : 27 
Gly Arg Gly Gly Arg Gly Lys 
< 210 > SEQ ID NO 28 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 28 
Gly Arg Arg Gly Gly Gly Lys 
< 210 > SEQ ID NO 29 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 29 
Gly Arg Gly Arg Gly Gly Lys 
1 
< 210 > SEQ ID NO 30 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 2 20 > FEATURE : 
US 9 , 937 , 256 B2 
- continued 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 30 
Gly Gly Arg Gly Arg Gly Lys 
< 210 > SEQ ID NO 31 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 




< 400 > SEQUENCE : 31 
Gly Lys Gly Gly Gly Gly Lys 
1 
< 210 > SEQ ID NO 32 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 32 
Gly Gly Lys Gly Gly Gly Lys 
< 210 > SEQ ID NO 33 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 33 
Gly Gly Gly Lys Gly Gly Lys 
< 210 > SEQ ID NO 34 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 34 
Gly Gly Gly Gly Lys Gly Lys 
< 210 > SEQ ID NO 35 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
M 
< 400 > SEQUENCE : 35 
Gly Lys Lys Gly Gly Gly Lys 
1 1 
< 210 > SEO ID NO 36 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
3 > OTHER INFORMATION : Synthetic p y c eptide A 
US 9 , 937 , 256 B2 
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- continued 
< 400 > SEQUENCE : 36 
Gly Gly Lys Lys Gly Gly Lys 
1 
< 210 > SEQ ID NO 37 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 37 
Gly Gly Gly Lys Lys Gly Lys 
5 
< 210 > SEQ ID NO 38 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 38 
Gly Gly Lys Gly Lys Gly Lys 
5 
< 210 > SEQ ID NO 39 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 2 13 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 
< 400 > SEQUENCE : 39 
Gly Lys Gly Lys Gly Gly Lys 
1 
? 
< 210 > SEQ ID NO 40 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
? 
M ??
< 400 > SEQUENCE : 40 
Gly Arg Lys Gly Gly Gly Lys 
? 
< 210 > SEQ ID NO 41 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
? NN HEOWN ? 
< 400 > SEQUENCE : 41 
Gly Gly Arg Lys Gly Gly Lys 
5 
V 
NNN HN NMO V 
< 210 > SEQ ID NO 42 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
US 9 , 937 , 256 B2 
65 
- continued 
< 400 > SEQUENCE : 42 
Gly Gly Gly Arg Lys Gly Lys 
1 
< 210 > SEQ ID NO 43 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 43 
Gly Gly Arg Gly Lys Gly Lys 
< 210 > SEQ ID NO 44 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
23 > OTHER INFORMATION : Synthetic peptide ? 
< 400 > SEQUENCE : 44 
Gly Arg Gly Lys Gly Gly Lys 
< 210 > SEQ ID NO 45 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 45 
Gly Lys Arg Gly Gly Gly Lys 
1 
? .
< 210 > SEQ ID NO 46 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 




< 400 > SEQUENCE : 46 
Gly Gly Lys Arg Gly Gly Lys 
< 210 > SEQ ID NO 47 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
M ???
? ?
< 400 > SEQUENCE : 47 
Gly Gly Gly Lys Arg Gly Lys 
1 
< 210 > SEQ ID NO 48 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
??? 
NNE ? ?
< 400 > SEQUENCE : 48 
US 9 , 937 , 256 B2 
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Gly Gly Lys Gly Arg Gly Lys 
< 210 > SEQ ID NO 49 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
20 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
V 
< 400 > SEQUENCE : 49 
Gly Lys Gly Arg Gly Gly Lys 
1 
< 210 > SEQ ID NO 50 
< 211 > LENGTH : 7 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide 
< 400 > SEQUENCE : 50 
Gly Lys Lys Lys Lys Gly Lys 
< 210 > SEQ ID NO 51 
< 211 > LENGTH : 21 
< 212 > TYPE : RNA 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic oligoribonucleotide 
< 400 > SEQUENCE : 51 
uaaggcuaug aagagauacu u 21 
< 210 > SEQ ID NO 52 
< 211 > LENGTH : 19 
< 212 > TYPE : RNA 
< 213 > ORGANISM : Artificial sequence 
20 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic oligoribonucleotide 
< 400 > SEQUENCE : 52 
cgucguagca aacc????? 19 
8 . The hydrogel of claim 7 , wherein the peptide comprises 
or consists of GRRRGK ( SEQ ID NO : 1 ) . 
9 . The hydrogel of claim 8 , wherein the peptide comprises 
the structure : 
HNNH , HNNH , 
HN HN . 
What is claimed is : 
1 . A hydrogel composed of a polymer , wherein the 
polymer comprises a poly ( methacrylic acid - co - N - vinylpyr - 50 ? 50 rolidone ) ( P ( MAA - CO - NVP ) ) copolymer that is crosslinked 
with an enzymatically cleavable peptide linker , wherein the hentide linker wherein the 
peptide linker consists of 3 - 25 amino acid residues and 
contains at least one lysine amino acid , wherein the hydrogel 
further comprises a therapeutic agent . 
2 . The hydrogel of claim 1 , wherein the peptide linker is 55 
cleavable by a serine protease , carboxypeptidase , or amino 
peptidase . 
3 . The hydrogel of claim 2 , wherein the serine protease is 
trypsin , chymotrypsin , or elastase . 
4 . The hydrogel of claim 3 , wherein the peptide linker isso 
cleavable by trypsin , wherein the trypsin is trypsin 1 , trypsin 
2 , or mesotrypsin . 
5 . The hydrogel of claim 1 , wherein the peptide is 4 - 20 
amino acid residues in length . 
6 . The hydrogel of claim 5 , wherein the peptide is 5 - 15 
amino acid residues in length . 
7 . The hydrogel of claim 6 , wherein the peptide is 5 - 10 
amino acid residues in length . 
O 
= N OH . min IZ NH IZ Ps 60 
HN 
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10 . The hydrogel of claim 8 , wherein the polymer com 11 . The hydrogel of claim 1 , wherein the polymer has 
prises the structure : been crosslinked with the peptide through the use of a 
coupling reagent . 
12 . The hydrogel of claim 11 , wherein the coupling 
HN NHA HN NH 5 reagent is a carbodiimide . 
13 . The hydrogel of claim 11 , wherein the polymer has 
been crosslinked with the peptide via an EDC - NHS reaction . 
14 . The hydrogel of claim 1 , wherein the hydrogel further 
comprises a polycationic nanoparticle . 
10 15 . The hydrogel of claim 14 , wherein the polycationic 
nanoparticle is substantially comprised within the hydrogel . 
16 . The hydrogel of claim 14 , wherein the polycationic 
NH Y nanoparticle comprises or consists of poly ( 2 - methoxyethy 
lacrylate ) ( PMEA ) , poly ( 2 - ( diethylaminoethyl ) methacry 
15 late ) ( PDEAEMA ) , chitosan , poly ( ethyleneimine ) ( PEI ) , 
poly ( amidoamine ) ( PAMAM ) , poly ( dimethylaminopropyl 
methacrylate ) ( PDMAPMA ) , poly ( 2 - aminoethyl methacry HN late ) ( PAEMA ) , or poly ( 2 - ( dimethylaminoethyl ) methacry 
late ) ( PDMAEMA ) . 
HN CNH , 2017 . The hydrogel of claim 1 , wherein the therapeutic agent 
is a therapeutic protein . 
18 . The hydrogel of claim 1 , wherein the therapeutic agent 
is a nucleic acid . 
19 . The hydrogel of claim 18 , wherein the nucleic acid is 
25 a small interfering RNA ( siRNA ) , a micro RNA ( miRNA ) , 
a short hairpin RNA ( shRNA ) , or an antisense oligonucle 
otide . 
20 . The hydrogel of claim 19 , wherein the nucleic acid is 
an siRNA . 
30 21 . A method of treating a disease comprising adminis 
tering the hydrogel of claim 1 to a mammalian subject in 
need of such treatment . 
22 . The method of claim 21 , wherein the administration is 
oral . 
HN 
NH OH . 
NH NH 
* * * * * 
